RyanT2021的个人主页 - 老虎社区

RyanT2021

RyanT2021

Ryan learns investing.

IP属地：未知

296关注

4粉丝

0主题

0勋章

2021-12-03

Grabair 😒

抱歉，原内容已删除

2021-12-01

Bad ama

New York accuses Amazon of backsliding over worker safety, seeks monitor

2021-11-30

Sigh new variant

Is Omicron The Catalyst That Ushers In The Next Bear Market?

2021-11-26

Hooray

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

2021-11-16

Ywah

抱歉，原内容已删除

2021-11-15

Good

Toshiba's top shareholder says undecided whether to support breakup

2021-11-13

Vaccine

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-11-09

Oh yeah AMD!

抱歉，原内容已删除

2021-11-08

Uh oh

抱歉，原内容已删除

2021-11-06

Cheers

Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer

2021-10-30

Uh oh

U.S. Supreme Court rejects religious challenge to Maine vaccine mandate

2021-10-29

Nicely

Gilead trims 2021 sales forecast for non-COVID products

2021-10-27

Uh oh

抱歉，原内容已删除

2021-10-26

Congrats Tiger

UP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited

2021-10-26

Oh wow nice

Sibanye Buys Brazil Mines in $1 Billion Battery Metals Push

2021-10-13

#hodl to the moon

What Is A Short Squeeze And What Is Going On In GameStop, AMC

2021-10-13

Oh no

Hong Kong stock exchange delays morning trading session due to typhoon

2021-10-07

Wow 1 bill

抱歉，原内容已删除

2021-10-07

Uh oh

Wall Street ends higher on optimism about U.S. debt-ceiling deal

2021-09-29

Hahah another fud by motley fool

Why AMC Stock Dropped Tuesday

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584238171442752","uuid":"3584238171442752","gmtCreate":1621150723051,"gmtModify":1621159965828,"name":"RyanT2021","pinyin":"ryant2021","introduction":"","introductionEn":null,"signature":"Ryan learns investing.","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":296,"tweetSize":60,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":601946359,"gmtCreate":1638487778267,"gmtModify":1638487778377,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Grabair 😒","listText":"Grabair 😒","text":"Grabair 😒","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601946359","repostId":"1191495883","repostType":2,"isVote":1,"tweetType":1,"viewCount":1639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609411200,"gmtCreate":1638317023022,"gmtModify":1638317023084,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Bad ama","listText":"Bad ama","text":"Bad ama","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609411200","repostId":"2188956532","repostType":4,"repost":{"id":"2188956532","kind":"news","pubTimestamp":1638316260,"share":"https://ttm.financial/m/news/2188956532?lang=&edition=full","pubTime":"2021-12-01 07:51","market":"us","language":"en","title":"New York accuses Amazon of backsliding over worker safety, seeks monitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2188956532","media":"StreetInsider","summary":"NEW YORK (Reuters) - New York state's attorney general on Tuesday asked a state judge to appoint a m","content":"<p>NEW YORK (Reuters) - New York state's attorney general on Tuesday asked a state judge to appoint a monitor to oversee worker safety at an Amazon.com Inc fulfillment center in New York City, citing the retailer's alleged rollbacks of COVID-19 safety measures that were \"already inadequate.\"</p>\n<p>Letitia James, the attorney general, also wants a court order requiring the rehiring of Christian Smalls, who Amazon fired for allegedly violating a paid quarantine by leading a March 2020 protest over conditions at the Staten Island facility.</p>\n<p>Amazon did not immediately respond to requests for comment.</p>\n<p>James, a Democrat running to become New York governor, sued Amazon in February in a New York state court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a> over its safety protocols for thousands of workers at the Staten Island facility and a distribution center in the New York City borough of Queens.</p>\n<p>She said Amazon is valuing profit over safety and \"acting as if the pandemic is over\" by rolling back safety protocols even as the Omicron variant of the COVID-19 virus threatens to increase transmission rates.</p>\n<p>The alleged rollbacks include making the Staten Island facility \"mask-optional\" for vaccinated workers while not requiring masks for unvaccinated workers, and failing to enforce social distancing.</p>\n<p>In her motion for a preliminary injunction, James said the proposed monitor would oversee upgraded cleaning, hygiene and social distancing procedures.</p>\n<p>\"While case rates, hospitalizations, and deaths rise, Amazon rescinds protections and packs in more workers for its holiday rush,\" James said in her motion. \"Amazon's ongoing - and worsening - failure to protect workers must be halted.\"</p>\n<p>The Seattle-based company is appealing a New York state judge's refusal in October to dismiss James' lawsuit.</p>\n<p>Amazon on Nov. 15 reached a separate settlement with California to resolve claims it violated a state \"right-to-know\" law by concealing from warehouse workers and local health agencies the numbers of workers being infected with COVID-19.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New York accuses Amazon of backsliding over worker safety, seeks monitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew York accuses Amazon of backsliding over worker safety, seeks monitor\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 07:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19291089><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - New York state's attorney general on Tuesday asked a state judge to appoint a monitor to oversee worker safety at an Amazon.com Inc fulfillment center in New York City, citing the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19291089\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4561":"索罗斯持仓","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4532":"文艺复兴科技持仓","BK4503":"景林资产持仓","BK4554":"元宇宙及AR概念","BK4122":"互联网与直销零售","AMZN":"亚马逊","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4559":"巴菲特持仓","BK4538":"云计算","BK4527":"明星科技股","BK4566":"资本集团"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19291089","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188956532","content_text":"NEW YORK (Reuters) - New York state's attorney general on Tuesday asked a state judge to appoint a monitor to oversee worker safety at an Amazon.com Inc fulfillment center in New York City, citing the retailer's alleged rollbacks of COVID-19 safety measures that were \"already inadequate.\"\nLetitia James, the attorney general, also wants a court order requiring the rehiring of Christian Smalls, who Amazon fired for allegedly violating a paid quarantine by leading a March 2020 protest over conditions at the Staten Island facility.\nAmazon did not immediately respond to requests for comment.\nJames, a Democrat running to become New York governor, sued Amazon in February in a New York state court in Manhattan over its safety protocols for thousands of workers at the Staten Island facility and a distribution center in the New York City borough of Queens.\nShe said Amazon is valuing profit over safety and \"acting as if the pandemic is over\" by rolling back safety protocols even as the Omicron variant of the COVID-19 virus threatens to increase transmission rates.\nThe alleged rollbacks include making the Staten Island facility \"mask-optional\" for vaccinated workers while not requiring masks for unvaccinated workers, and failing to enforce social distancing.\nIn her motion for a preliminary injunction, James said the proposed monitor would oversee upgraded cleaning, hygiene and social distancing procedures.\n\"While case rates, hospitalizations, and deaths rise, Amazon rescinds protections and packs in more workers for its holiday rush,\" James said in her motion. \"Amazon's ongoing - and worsening - failure to protect workers must be halted.\"\nThe Seattle-based company is appealing a New York state judge's refusal in October to dismiss James' lawsuit.\nAmazon on Nov. 15 reached a separate settlement with California to resolve claims it violated a state \"right-to-know\" law by concealing from warehouse workers and local health agencies the numbers of workers being infected with COVID-19.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":1470,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609145054,"gmtCreate":1638257987846,"gmtModify":1638257987989,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Sigh new variant","listText":"Sigh new variant","text":"Sigh new variant","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609145054","repostId":"1171526526","repostType":4,"repost":{"id":"1171526526","kind":"news","pubTimestamp":1638257648,"share":"https://ttm.financial/m/news/1171526526?lang=&edition=full","pubTime":"2021-11-30 15:34","market":"us","language":"en","title":"Is Omicron The Catalyst That Ushers In The Next Bear Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=1171526526","media":"TheStreet","summary":"Investors got rattled last Friday, but could the new COVID variant be the thing that finally topples stocks?","content":"<p>There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&amp;P 500 to its largest single day loss since February and the Russell 2000 to its largest single day loss since June of last year. The reveal of a potentially more mutated and more highly contagious version of both the original COVID strain and the delta variant brought investors back to the early days of the pandemic when businesses, schools and other groups were suddenly forced to shut down.</p>\n<p>Is it going to be as big of a deal as the markets fear it might be? It’s too early to know for sure (although the South African Medical Association seems to be&nbsp;downplaying&nbsp;the severity of it), but global governments appear to be taking no chances. Several countries have shut down their borders to people from South Africa and neighboring countries. New York has already&nbsp;declared&nbsp;a state of emergency despite no reported cases of the omicron variant. Of course, there’s still much to learn about the risk level of this COVID strain, but it’s clear that nerves are a bit frayed.</p>\n<p>In my opinion, Friday’s sharp equity pullback looks like a classic overreaction. Yes, there’s a distinct possibility that it may not be the bottom and equities could sell off further, but given how investors have been prolific dip buyers over the past year and expectations for the taper and future interest rate hikes turned immediately dovish, per the Fed Funds futures market, I think investors will quickly conclude that the omicron variant will likely not be as bad as anticipated and, even if it is, the Fed will quickly step in, whether it’s via a delayed taper or no rate hike until 2023, to support risk asset prices. If I’m going out on a limb, I think there’s a chance the S&amp;P 500 could recapture its all-time high (it’s currently about 2.3% below it) by the end of this week.</p>\n<p>Market internals had already been softening leading up to last week. Breadth within the Nasdaq 100 has been getting weaker - 30 of the 100 components have&nbsp;pulled back&nbsp;at least 20%. Small-caps have been underperforming for weeks and leadership has rotated away from cyclicals and back into tech and consumer discretionary. Treasuries are looking strong again and even gold has been seeing some action.</p>\n<p>Fear is high in the markets right now and that presents opportunity. Keep a level head and watch for panic signs (e.g. the number of articles talking about how stocks could pull back 30% from here) and words from the Fed that hint at what the central bank might do. Remember, in 2020 after the initial bear market, stocks rebounded quickly as soon as the Fed and the government stepped in. If Powell pivots to a more dovish stance, U.S. equities could quickly move higher again.</p>\n<p>Let’s start our weekly review by taking a look at the primary market sectors.</p>\n<p><img src=\"https://static.tigerbbs.com/d87d1ba9c165a777608a551646236565\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Not surprisingly, there’s little short-term strength in equities right now. Communication services remains the worst-looking of the 11 major sectors, but cyclicals are not that far behind. Energy stocks were down 4% on Friday as crude oil prices dropped more than 10%, but still managed to gain more than 1% on the week as a whole. Financials are weaker on falling interest rates, but industrials and materials are similarly well off recent highs.</p>\n<p>As I mentioned above, tech and consumer discretionary have been the beneficiaries of rotation trades lately. Tech had become a steady outperformer before last week’s correction, while discretionary stocks have gained but remained volatile. Four of the 11 GICS sectors are now trading below their 50-day moving averages, which could be an indication that short-term momentum has run its course and it may be time for defensives to take over.</p>\n<p>The performance of small-caps, Treasuries and cyclicals point to more conservative positioning even before Friday. Utilities and consumer staples did relatively better as expected, but it’s been a while since either group had an extended run. This week will be telling, I think, in determining where investor risk tolerance is really at. If omicron looks like it will keep drawing out people’s fears, there might be room for defensive sectors to perform relatively well. Keep in mind that it’ll be all about business and social restrictions. If the economic impact is limited mostly to the leisure and travel sectors, the longer-term damage could be minimal.</p>\n<p><img src=\"https://static.tigerbbs.com/cbc4d98c13f73357d48d25a67a1ed80e\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Short-term strength has fallen pretty much across the board, but with a few exceptions. Semiconductor stocks had a rough week along with the rest of the tech sector, but they remain one of the best performing groups throughout 2021. Homebuilder stocks continue to build on the strength in the housing, which, despite some stops and starts in sales, demand and commodity prices, been pretty consistent.</p>\n<p>No surprise that the casino, leisure and recreation stocks are getting hit the hardest. These, of course, are the first to get hit in an environment like this. New travel restrictions are already being put in place and we’re very likely to see even more in the coming weeks. As we’ve seen with New York, there’s been little hesitation so far to put mitigation efforts in place. Oil prices and energy demand forecasts have taken a hit adding to the pressure.</p>\n<p>No major changes in the communication services sector. We’re still seeing weakness throughout, including the social media stocks, which continue to have a hard time reversing sentiment. The traditional telecoms were virtually changed this past week and could actually become a source of support should prices continue falling here.</p>\n<p><img src=\"https://static.tigerbbs.com/b04029e09b601d3f39d2cfc0be349d00\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Oil prices got hammered last week, which led to 5-6% losses for the explorers and servicers. The broader energy sector did comparatively better, but even clean energy posted a loss of 4% indicating little support across the board. Short-term sentiment for this sector has largely disappeared and the huge returns of earlier this year have long since been forgotten. This will be an especially omicron-dependent sector this week, so expect some above average volatility. Flow numbers show that investors are abandoning ship.</p>\n<p>Just like the leisure sector, the airlines are especially weak here, but there’s really no group within the cyclicals that’s doing OK. The gold &amp; silver miners had a moment in the sun, but with gold prices appearing to have lost their momentum again, they’ve been back on the downswing. Infrastructure stock returns have largely been a function of the passage of the infrastructure bill, but that momentum it also likely to begin fading.</p>\n<p><img src=\"https://static.tigerbbs.com/4d74ecebe8c9240855b76ea5a23034f4\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Healthcare is starting to look a little, well, healthier again. Most of it looks like it’s due to its defensive sector peers starting to draw a little interest again, but any kind of health-related headlines, such as a new COVID variant, tend to produce at least a modest short-term bounce. Both Moderna and BioNTech, the makers of different COVID vaccines, were both up more than 20% last week alone and that’s making the biotech sector look a little stronger than it is. The&nbsp;<b>SPDR S&amp;P Biotech ETF (XBI)</b>, which equal weights the sector and gives much less weight to those names, was down 4% last week. There is some money moving back into this space, but I don’t think it’s a compelling move just yet.</p>\n<p>Not much doing on the commodities side. Crude and gasoline prices have plummeted, but natural gas prices have held their ground. I suspect that there’s some mean reversion in energy prices following Friday’s overreaction. The dollar remains very strong against the basket of global currencies although we’ll have to see if the omicron variant impacts that. Its strength has come on the back of comparatively higher interest rates and better economic growth readings. The plans for tapering and rate hikes may be pushed back now, which could bring the dollar back down.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Omicron The Catalyst That Ushers In The Next Bear Market?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Omicron The Catalyst That Ushers In The Next Bear Market?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 15:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&P 500 to its ...</p>\n\n<a href=\"https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171526526","content_text":"There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&P 500 to its largest single day loss since February and the Russell 2000 to its largest single day loss since June of last year. The reveal of a potentially more mutated and more highly contagious version of both the original COVID strain and the delta variant brought investors back to the early days of the pandemic when businesses, schools and other groups were suddenly forced to shut down.\nIs it going to be as big of a deal as the markets fear it might be? It’s too early to know for sure (although the South African Medical Association seems to be downplaying the severity of it), but global governments appear to be taking no chances. Several countries have shut down their borders to people from South Africa and neighboring countries. New York has already declared a state of emergency despite no reported cases of the omicron variant. Of course, there’s still much to learn about the risk level of this COVID strain, but it’s clear that nerves are a bit frayed.\nIn my opinion, Friday’s sharp equity pullback looks like a classic overreaction. Yes, there’s a distinct possibility that it may not be the bottom and equities could sell off further, but given how investors have been prolific dip buyers over the past year and expectations for the taper and future interest rate hikes turned immediately dovish, per the Fed Funds futures market, I think investors will quickly conclude that the omicron variant will likely not be as bad as anticipated and, even if it is, the Fed will quickly step in, whether it’s via a delayed taper or no rate hike until 2023, to support risk asset prices. If I’m going out on a limb, I think there’s a chance the S&P 500 could recapture its all-time high (it’s currently about 2.3% below it) by the end of this week.\nMarket internals had already been softening leading up to last week. Breadth within the Nasdaq 100 has been getting weaker - 30 of the 100 components have pulled back at least 20%. Small-caps have been underperforming for weeks and leadership has rotated away from cyclicals and back into tech and consumer discretionary. Treasuries are looking strong again and even gold has been seeing some action.\nFear is high in the markets right now and that presents opportunity. Keep a level head and watch for panic signs (e.g. the number of articles talking about how stocks could pull back 30% from here) and words from the Fed that hint at what the central bank might do. Remember, in 2020 after the initial bear market, stocks rebounded quickly as soon as the Fed and the government stepped in. If Powell pivots to a more dovish stance, U.S. equities could quickly move higher again.\nLet’s start our weekly review by taking a look at the primary market sectors.\n\nNot surprisingly, there’s little short-term strength in equities right now. Communication services remains the worst-looking of the 11 major sectors, but cyclicals are not that far behind. Energy stocks were down 4% on Friday as crude oil prices dropped more than 10%, but still managed to gain more than 1% on the week as a whole. Financials are weaker on falling interest rates, but industrials and materials are similarly well off recent highs.\nAs I mentioned above, tech and consumer discretionary have been the beneficiaries of rotation trades lately. Tech had become a steady outperformer before last week’s correction, while discretionary stocks have gained but remained volatile. Four of the 11 GICS sectors are now trading below their 50-day moving averages, which could be an indication that short-term momentum has run its course and it may be time for defensives to take over.\nThe performance of small-caps, Treasuries and cyclicals point to more conservative positioning even before Friday. Utilities and consumer staples did relatively better as expected, but it’s been a while since either group had an extended run. This week will be telling, I think, in determining where investor risk tolerance is really at. If omicron looks like it will keep drawing out people’s fears, there might be room for defensive sectors to perform relatively well. Keep in mind that it’ll be all about business and social restrictions. If the economic impact is limited mostly to the leisure and travel sectors, the longer-term damage could be minimal.\n\nShort-term strength has fallen pretty much across the board, but with a few exceptions. Semiconductor stocks had a rough week along with the rest of the tech sector, but they remain one of the best performing groups throughout 2021. Homebuilder stocks continue to build on the strength in the housing, which, despite some stops and starts in sales, demand and commodity prices, been pretty consistent.\nNo surprise that the casino, leisure and recreation stocks are getting hit the hardest. These, of course, are the first to get hit in an environment like this. New travel restrictions are already being put in place and we’re very likely to see even more in the coming weeks. As we’ve seen with New York, there’s been little hesitation so far to put mitigation efforts in place. Oil prices and energy demand forecasts have taken a hit adding to the pressure.\nNo major changes in the communication services sector. We’re still seeing weakness throughout, including the social media stocks, which continue to have a hard time reversing sentiment. The traditional telecoms were virtually changed this past week and could actually become a source of support should prices continue falling here.\n\nOil prices got hammered last week, which led to 5-6% losses for the explorers and servicers. The broader energy sector did comparatively better, but even clean energy posted a loss of 4% indicating little support across the board. Short-term sentiment for this sector has largely disappeared and the huge returns of earlier this year have long since been forgotten. This will be an especially omicron-dependent sector this week, so expect some above average volatility. Flow numbers show that investors are abandoning ship.\nJust like the leisure sector, the airlines are especially weak here, but there’s really no group within the cyclicals that’s doing OK. The gold & silver miners had a moment in the sun, but with gold prices appearing to have lost their momentum again, they’ve been back on the downswing. Infrastructure stock returns have largely been a function of the passage of the infrastructure bill, but that momentum it also likely to begin fading.\n\nHealthcare is starting to look a little, well, healthier again. Most of it looks like it’s due to its defensive sector peers starting to draw a little interest again, but any kind of health-related headlines, such as a new COVID variant, tend to produce at least a modest short-term bounce. Both Moderna and BioNTech, the makers of different COVID vaccines, were both up more than 20% last week alone and that’s making the biotech sector look a little stronger than it is. The SPDR S&P Biotech ETF (XBI), which equal weights the sector and gives much less weight to those names, was down 4% last week. There is some money moving back into this space, but I don’t think it’s a compelling move just yet.\nNot much doing on the commodities side. Crude and gasoline prices have plummeted, but natural gas prices have held their ground. I suspect that there’s some mean reversion in energy prices following Friday’s overreaction. The dollar remains very strong against the basket of global currencies although we’ll have to see if the omicron variant impacts that. Its strength has come on the back of comparatively higher interest rates and better economic growth readings. The plans for tapering and rate hikes may be pushed back now, which could bring the dollar back down.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877689986,"gmtCreate":1637924331182,"gmtModify":1637924331182,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Hooray","listText":"Hooray","text":"Hooray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877689986","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://ttm.financial/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"NVS":0.9,"RHHBY":0.9}},"isVote":1,"tweetType":1,"viewCount":1959,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871399532,"gmtCreate":1637023887635,"gmtModify":1637023887694,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Ywah","listText":"Ywah","text":"Ywah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871399532","repostId":"1140879609","repostType":4,"isVote":1,"tweetType":1,"viewCount":2739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873685953,"gmtCreate":1636938238621,"gmtModify":1636938238725,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873685953","repostId":"2183048749","repostType":4,"repost":{"id":"2183048749","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1636935843,"share":"https://ttm.financial/m/news/2183048749?lang=&edition=full","pubTime":"2021-11-15 08:24","market":"us","language":"en","title":"Toshiba's top shareholder says undecided whether to support breakup","url":"https://stock-news.laohu8.com/highlight/detail?id=2183048749","media":"Reuters","summary":"TOKYO, Nov 13 (Reuters) - Toshiba Corp's biggest investor Effissimo Capital Management said on Satur","content":"<p>TOKYO, Nov 13 (Reuters) - Toshiba Corp's biggest investor Effissimo Capital Management said on Saturday it has not decided whether to support plans outlined by the Japanese industrial conglomerate to split into three companies.</p>\n<p>Toshiba outlined plans&nbsp;on Friday to split into three companies in an attempt to appease activist shareholders calling for a radical overhaul of the Japanese conglomerate after years of scandals.</p>\n<p>Singapore-based Effissimo, which owns a 9.9% stake in Toshiba, issued a statement after a Japanese broadcaster cited an Effissimo-related source as saying the fund wouldn't support the plans.</p>\n<p>The fund will decide its stance by Toshiba's extraordinary shareholders meeting next year \"following sincere considerations based on analysis of disclosed information as well as through engagement with the company,\" the statement said.</p>\n<p>Toshiba declined to comment on the Effissimo statement. \"We hope to hear sincere opinions from shareholders after we explain thoroughly to seek their understanding about the plans,\" it said in a emailed statement.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toshiba's top shareholder says undecided whether to support breakup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToshiba's top shareholder says undecided whether to support breakup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-15 08:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Nov 13 (Reuters) - Toshiba Corp's biggest investor Effissimo Capital Management said on Saturday it has not decided whether to support plans outlined by the Japanese industrial conglomerate to split into three companies.</p>\n<p>Toshiba outlined plans&nbsp;on Friday to split into three companies in an attempt to appease activist shareholders calling for a radical overhaul of the Japanese conglomerate after years of scandals.</p>\n<p>Singapore-based Effissimo, which owns a 9.9% stake in Toshiba, issued a statement after a Japanese broadcaster cited an Effissimo-related source as saying the fund wouldn't support the plans.</p>\n<p>The fund will decide its stance by Toshiba's extraordinary shareholders meeting next year \"following sincere considerations based on analysis of disclosed information as well as through engagement with the company,\" the statement said.</p>\n<p>Toshiba declined to comment on the Effissimo statement. \"We hope to hear sincere opinions from shareholders after we explain thoroughly to seek their understanding about the plans,\" it said in a emailed statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TOSYY":"东芝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183048749","content_text":"TOKYO, Nov 13 (Reuters) - Toshiba Corp's biggest investor Effissimo Capital Management said on Saturday it has not decided whether to support plans outlined by the Japanese industrial conglomerate to split into three companies.\nToshiba outlined plans on Friday to split into three companies in an attempt to appease activist shareholders calling for a radical overhaul of the Japanese conglomerate after years of scandals.\nSingapore-based Effissimo, which owns a 9.9% stake in Toshiba, issued a statement after a Japanese broadcaster cited an Effissimo-related source as saying the fund wouldn't support the plans.\nThe fund will decide its stance by Toshiba's extraordinary shareholders meeting next year \"following sincere considerations based on analysis of disclosed information as well as through engagement with the company,\" the statement said.\nToshiba declined to comment on the Effissimo statement. \"We hope to hear sincere opinions from shareholders after we explain thoroughly to seek their understanding about the plans,\" it said in a emailed statement.","news_type":1,"symbols_score_info":{"TOSYY":0.9}},"isVote":1,"tweetType":1,"viewCount":1126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879786919,"gmtCreate":1636773124448,"gmtModify":1636773124448,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Vaccine","listText":"Vaccine","text":"Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879786919","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://ttm.financial/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844617599,"gmtCreate":1636422002353,"gmtModify":1636422009758,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh yeah AMD!","listText":"Oh yeah AMD!","text":"Oh yeah AMD!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/844617599","repostId":"2182113779","repostType":4,"isVote":1,"tweetType":1,"viewCount":1501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845842779,"gmtCreate":1636331128796,"gmtModify":1636331128935,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845842779","repostId":"1125924899","repostType":4,"isVote":1,"tweetType":1,"viewCount":1716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842838016,"gmtCreate":1636160870694,"gmtModify":1636160948481,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Cheers","listText":"Cheers","text":"Cheers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842838016","repostId":"1173813098","repostType":4,"repost":{"id":"1173813098","kind":"news","pubTimestamp":1636156499,"share":"https://ttm.financial/m/news/1173813098?lang=&edition=full","pubTime":"2021-11-06 07:54","market":"us","language":"en","title":"Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=1173813098","media":"Reuters","summary":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains ","content":"<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.</p>\n<p>The S&amp;P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.</p>\n<p>The Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.</p>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.</p>\n<p>The news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.</p>\n<p>\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.</p>\n<p>The Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&amp;P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.</p>\n<p>For the week, the S&amp;P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.</p>\n<p>Travel stocks rose following Pfizer's announcement, with the S&amp;P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.</p>\n<p>\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.</p>\n<p>Among S&amp;P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.</p>\n<p>Healthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.</p>\n<p>Shares of so-called \"stay-at-home\" names fell, with <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications down 6.2% and Netflix Inc off 3.4%.</p>\n<p>Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.</p>\n<p>Pinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.</p>\n<p>Peloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.</p>\n<p>About 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 07:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19167545><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19167545\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","PFE":"辉瑞",".SPX":"S&P 500 Index"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19167545","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173813098","content_text":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.\nThe S&P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.\nThe Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.\nA trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.\nThe news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.\n\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.\nThe Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.\nFor the week, the S&P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.\nTravel stocks rose following Pfizer's announcement, with the S&P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.\n\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.\nAmong S&P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.\nHealthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.\nShares of so-called \"stay-at-home\" names fell, with Zoom Video Communications down 6.2% and Netflix Inc off 3.4%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.\nPinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.\nPeloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.\nThe S&P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.\nAbout 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857460294,"gmtCreate":1635555751407,"gmtModify":1635555751407,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857460294","repostId":"2179240376","repostType":4,"repost":{"id":"2179240376","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635543522,"share":"https://ttm.financial/m/news/2179240376?lang=&edition=full","pubTime":"2021-10-30 05:38","market":"us","language":"en","title":"U.S. Supreme Court rejects religious challenge to Maine vaccine mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2179240376","media":"Reuters","summary":"WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeki","content":"<p>WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeking a religious exemption to Maine's COVID-19 vaccine mandate in the latest battle over vaccination to reach the justices.</p>\n<p>The court rejected a request made by nine unnamed plaintiffs who identified themselves as healthcare workers who object to receiving the shots on religious grounds. The court previously rejected challenges to vaccine mandates in New York and Indiana, though those cases did not involve religious objections.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Supreme Court rejects religious challenge to Maine vaccine mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Supreme Court rejects religious challenge to Maine vaccine mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-30 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeking a religious exemption to Maine's COVID-19 vaccine mandate in the latest battle over vaccination to reach the justices.</p>\n<p>The court rejected a request made by nine unnamed plaintiffs who identified themselves as healthcare workers who object to receiving the shots on religious grounds. The court previously rejected challenges to vaccine mandates in New York and Indiana, though those cases did not involve religious objections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179240376","content_text":"WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeking a religious exemption to Maine's COVID-19 vaccine mandate in the latest battle over vaccination to reach the justices.\nThe court rejected a request made by nine unnamed plaintiffs who identified themselves as healthcare workers who object to receiving the shots on religious grounds. The court previously rejected challenges to vaccine mandates in New York and Indiana, though those cases did not involve religious objections.","news_type":1,"symbols_score_info":{"STS":0.9}},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854245705,"gmtCreate":1635465395781,"gmtModify":1635465395921,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854245705","repostId":"1147570640","repostType":4,"repost":{"id":"1147570640","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635463369,"share":"https://ttm.financial/m/news/1147570640?lang=&edition=full","pubTime":"2021-10-29 07:22","market":"us","language":"en","title":"Gilead trims 2021 sales forecast for non-COVID products","url":"https://stock-news.laohu8.com/highlight/detail?id=1147570640","media":"Reuters","summary":"Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earning","content":"<p>Oct 28 (Reuters) - Gilead Sciences Inc&nbsp;on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.</p>\n<p>Without Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.</p>\n<p>Gilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.</p>\n<p>The biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.</p>\n<p>\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.</p>\n<p>The company's shares, which closed at $67.34, were down 2% at $66 in extended trading.</p>\n<p><img src=\"https://static.tigerbbs.com/bb57f1c1d44cce1af6c37e25db1f4a49\" tg-width=\"847\" tg-height=\"621\" width=\"100%\" height=\"auto\"></p>\n<p>Gilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.</p>\n<p>Revenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.</p>\n<p>But the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.</p>\n<p>Gilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.</p>\n<p>Use of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.</p>\n<p>Third-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.</p>\n<p>Sales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.</p>\n<p>Gilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.</p>\n<p>Including Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead trims 2021 sales forecast for non-COVID products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead trims 2021 sales forecast for non-COVID products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-29 07:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Oct 28 (Reuters) - Gilead Sciences Inc&nbsp;on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.</p>\n<p>Without Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.</p>\n<p>Gilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.</p>\n<p>The biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.</p>\n<p>\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.</p>\n<p>The company's shares, which closed at $67.34, were down 2% at $66 in extended trading.</p>\n<p><img src=\"https://static.tigerbbs.com/bb57f1c1d44cce1af6c37e25db1f4a49\" tg-width=\"847\" tg-height=\"621\" width=\"100%\" height=\"auto\"></p>\n<p>Gilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.</p>\n<p>Revenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.</p>\n<p>But the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.</p>\n<p>Gilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.</p>\n<p>Use of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.</p>\n<p>Third-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.</p>\n<p>Sales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.</p>\n<p>Gilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.</p>\n<p>Including Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147570640","content_text":"Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.\nWithout Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.\nGilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.\nThe biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.\n\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.\nThe company's shares, which closed at $67.34, were down 2% at $66 in extended trading.\n\nGilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.\nRevenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.\nBut the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.\nGilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.\nUse of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.\nThird-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.\nSales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.\nGilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.\nIncluding Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855941229,"gmtCreate":1635329421608,"gmtModify":1635329421709,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855941229","repostId":"1130740347","repostType":4,"isVote":1,"tweetType":1,"viewCount":771,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852945165,"gmtCreate":1635237168906,"gmtModify":1635237630982,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Congrats Tiger","listText":"Congrats Tiger","text":"Congrats Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/852945165","repostId":"1134836974","repostType":4,"repost":{"id":"1134836974","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635235567,"share":"https://ttm.financial/m/news/1134836974?lang=&edition=full","pubTime":"2021-10-26 16:06","market":"us","language":"en","title":"UP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=1134836974","media":"Tiger Newspress","summary":"BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” o","content":"<p>BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.</p>\n<p>The Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.</p>\n<p>About UP Fintech Holding Limited</p>\n<p>UP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.</p>\n<p>For more information on the Company, please visit：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-26 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.</p>\n<p>The Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.</p>\n<p>About UP Fintech Holding Limited</p>\n<p>UP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.</p>\n<p>For more information on the Company, please visit：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TIGR":"老虎证券"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134836974","content_text":"BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.\nThe Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.\nAbout UP Fintech Holding Limited\nUP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.\nFor more information on the Company, please visit：https://ir.itiger.com","news_type":1,"symbols_score_info":{"TIGR":0.9}},"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852945931,"gmtCreate":1635237133809,"gmtModify":1635237630604,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh wow nice","listText":"Oh wow nice","text":"Oh wow nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/852945931","repostId":"1111450640","repostType":4,"repost":{"id":"1111450640","kind":"news","pubTimestamp":1635236948,"share":"https://ttm.financial/m/news/1111450640?lang=&edition=full","pubTime":"2021-10-26 16:29","market":"us","language":"en","title":"Sibanye Buys Brazil Mines in $1 Billion Battery Metals Push","url":"https://stock-news.laohu8.com/highlight/detail?id=1111450640","media":"Bloomberg","summary":"Sibanye Stillwater Ltd. agreed to pay $1 billion in cash for nickel and copper mines in Brazil, in a","content":"<p>Sibanye Stillwater Ltd. agreed to pay $1 billion in cash for nickel and copper mines in Brazil, in a deal that highlights the race to supply battery metals to the booming electric-vehicle sector.</p>\n<p>Nickel, traditionally used to make stainless steel, is a key component in lithium-ion batteries and a favorite talking point of Elon Musk, who appealed to producers last year to “please mine more nickel.” That’s sparked a fight over nickel mines as the industry gears up for the green transition.</p>\n<p>Flush with cash from a rally in the rhodium and palladium it mines in South Africa, Sibanye has joined the push into battery metals. Chief Executive Officer Neal Froneman has already acquired lithium assets in Europe and the U.S. this year and the purchase of Santa Rita -- one of the largest nickel-cobalt sulphide mines in the world -- furthers his ambitions.</p>\n<p>“This transaction is a further meaningful step -- adding two low-cost, producing assets to its green metals portfolio,” Johannesburg-based Sibanye said in a statement Tuesday.</p>\n<p>Sibanye climbed 3.5% in Johannesburg trading, paring this year’s loss to 11%. The shares dropped 5.1% on Monday, after the company said it was in talks to buy the mines.</p>\n<p>Santa Rita, along with the purchase of the Serrote copper mine, offers “substantial” long-term potential, the company said. The deal to acquire the mines from affiliates of funds advised by Appian Capital Advisory LLP also includes a smelter royalty valued at $218 million, Sibanye said.</p>\n<p>“The transaction also highlights the strong and growing demand for decarbonisation commodities,” Michael Scherb, CEO and founder of Appian, said in a statement.</p>\n<p>Since its formation in 2013, after Gold Fields Ltd. spun off its oldest South African gold mines, dealmaking CEO Froneman has transformed Sibanye through the acquisition of platinum-group metals assets from Zimbabwe to Montana. Now he wants battery metals to contribute about a third of Sibanye’s earnings within four years as the transition to a greener economy spurs demand.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sibanye Buys Brazil Mines in $1 Billion Battery Metals Push</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSibanye Buys Brazil Mines in $1 Billion Battery Metals Push\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-26 16:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sibanye-buys-brazil-mines-1-072252607.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sibanye Stillwater Ltd. agreed to pay $1 billion in cash for nickel and copper mines in Brazil, in a deal that highlights the race to supply battery metals to the booming electric-vehicle sector.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/sibanye-buys-brazil-mines-1-072252607.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SBYSF":"Sibanye Stillwater LTD."},"source_url":"https://finance.yahoo.com/news/sibanye-buys-brazil-mines-1-072252607.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111450640","content_text":"Sibanye Stillwater Ltd. agreed to pay $1 billion in cash for nickel and copper mines in Brazil, in a deal that highlights the race to supply battery metals to the booming electric-vehicle sector.\nNickel, traditionally used to make stainless steel, is a key component in lithium-ion batteries and a favorite talking point of Elon Musk, who appealed to producers last year to “please mine more nickel.” That’s sparked a fight over nickel mines as the industry gears up for the green transition.\nFlush with cash from a rally in the rhodium and palladium it mines in South Africa, Sibanye has joined the push into battery metals. Chief Executive Officer Neal Froneman has already acquired lithium assets in Europe and the U.S. this year and the purchase of Santa Rita -- one of the largest nickel-cobalt sulphide mines in the world -- furthers his ambitions.\n“This transaction is a further meaningful step -- adding two low-cost, producing assets to its green metals portfolio,” Johannesburg-based Sibanye said in a statement Tuesday.\nSibanye climbed 3.5% in Johannesburg trading, paring this year’s loss to 11%. The shares dropped 5.1% on Monday, after the company said it was in talks to buy the mines.\nSanta Rita, along with the purchase of the Serrote copper mine, offers “substantial” long-term potential, the company said. The deal to acquire the mines from affiliates of funds advised by Appian Capital Advisory LLP also includes a smelter royalty valued at $218 million, Sibanye said.\n“The transaction also highlights the strong and growing demand for decarbonisation commodities,” Michael Scherb, CEO and founder of Appian, said in a statement.\nSince its formation in 2013, after Gold Fields Ltd. spun off its oldest South African gold mines, dealmaking CEO Froneman has transformed Sibanye through the acquisition of platinum-group metals assets from Zimbabwe to Montana. Now he wants battery metals to contribute about a third of Sibanye’s earnings within four years as the transition to a greener economy spurs demand.","news_type":1,"symbols_score_info":{"SBYSF":0.9}},"isVote":1,"tweetType":1,"viewCount":417,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822140419,"gmtCreate":1634105603856,"gmtModify":1634105604027,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"#hodl to the moon&nbsp;","listText":"#hodl to the moon&nbsp;","text":"#hodl to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822140419","repostId":"1107758297","repostType":4,"repost":{"id":"1107758297","kind":"news","pubTimestamp":1634088266,"share":"https://ttm.financial/m/news/1107758297?lang=&edition=full","pubTime":"2021-10-13 09:24","market":"us","language":"en","title":"What Is A Short Squeeze And What Is Going On In GameStop, AMC","url":"https://stock-news.laohu8.com/highlight/detail?id=1107758297","media":"investors","summary":"What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make ","content":"<p>What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make truly staggering jumps, doubling in price on consecutive days. There are several factors that are contributing to these gargantuan moves, but one is surely the classic short squeeze.</p>\n<p>While there are some new factors at play in the markets today, the short squeeze has been around as long as shorting stock.</p>\n<p>What Is A Short Squeeze</p>\n<p>Here is how the short squeeze works. If traders think a stock's price is going lower, they canshort the stock. They borrow shares and sell them, with the intent of buying them back at lower prices.</p>\n<p>This is mostly done by institutional investors, like hedge funds, given the risks and the margin required.</p>\n<p>And there are big risks. Stocks can theoretically go up infinitely. So a&nbsp;trader who is short&nbsp;can face theoretically infinite losses.</p>\n<p>Some stocks attract&nbsp;very high short interest, which can be viewed as the amount of shares sold short as a percentage of float, or how much stock has been issued that is available for trading.</p>\n<p>The problem comes if the stock prices starts to rise quickly. Those that are short the stock will likely receive a margin call. They either have to put more money up to secure their position or close their positions.</p>\n<p>If they choose to — or are forced to — close their position, they are buying the stock to close out their position. This can push the price higher and force other short sellers to do the same. This creates a reinforcing loop of buying and pushing the price higher. This is the short squeeze, as those short the market get \"squeezed\" out.</p>\n<p>Short Squeeze Stocks: GME</p>\n<p>This is definitely part of what was happening in&nbsp;<b>GameStop</b>(GME) stock. In August of 2020, GME stock was trading for around 4.</p>\n<p>Shares steadily climbed higher to close out 2020 just under 20 on the back of some big name investors taking stakes in the company. This attracted the short sellers, notably some big hedge funds. Then, on Jan. 13, the stock jumped to hit a high of almost 40 on huge volume.</p>\n<p>That was surely the start of the short squeeze. That 40 level held for about a week. On Jan. 22, the stock jumped again, trading above 70 on the biggest volume day up to that point.</p>\n<p>The next day the stock hit a high of almost 160 with similar action the next day. Then on Jan. 27 the stock doubled again, trading up to 380. The Jan. 28 high was 483.</p>\n<p>While short squeezes are nothing new, this action is unprecedented. The action is certainly partly stock buying by the Reddit group wallstreetbets.</p>\n<p>And while many are cheering that the little retail traders are beating up the big institutional shorts, it is pretty clear that other institutions are also in on this buying. Stories have popped up about Michael Burry's gains on GME stock and Elon Musk was tweeting about it.</p>\n<p>Hedge Fund Losses</p>\n<p>There are some big losses in this squeeze.</p>\n<p>Two funds in particular have been hard hit. Citron Research and Melvin Capital have reportedly suffered huge losses.</p>\n<p>Melvin is down 30% in 2021 on the back of a GME stock short position. It turned to Steven Cohen of Point72 Capital and Chicago-based Citadel to bail it out.</p>\n<p>The short squeeze is usually something inflicted by one hedge fund on another.</p>\n<p>This is really the first time we have seen such trading instigated by a band of retail traders.</p>\n<p>Options Trading Is Also A Big Factor</p>\n<p>Another piece of this story's plot is the fact that much of the trading in GME and other names like&nbsp;<b>AMC Entertainment</b>(AMC) and&nbsp;<b>BlackBerry</b>(BB) is actually taking place in the&nbsp;options market.</p>\n<p>Bullish call buying instead of buying the stock is attractive here because of the leverage it provides and the fact that the positions are limited risk.</p>\n<p>Calls are contracts that give the right to buy the underlying stock for a given price (strike price) until the expiration date.</p>\n<p>The most that can be lost is the premium paid for the calls.</p>\n<p>Buying calls requires much less capital, so bigger positions can be taken by small traders.</p>\n<p>This actually adds to the short squeeze effect.</p>\n<p>When retail traders buy calls, it is market makers that sell them.</p>\n<p>The market makers don't want the risk of being short calls, so they do something called delta hedging.</p>\n<p>What Is Delta Hedging, And Why It Matters In A Short Squeeze</p>\n<p>Delta hedging calls requires the market makers to buy stock. And because of the nature of calls, when the price of the underlying stock goes up, the market makers have to buy more stock to stay hedged.</p>\n<p>We might call this the call option squeeze.</p>\n<p>The problem is that these moves are not based on any fundamental changes in the stocks.</p>\n<p>Not much has changed for GME stock since it was a $4 stock, and certainly not since it was a $16 stock.</p>\n<p>Brokerage firms are very concerned about the volatility of these moves, as they know they may face losses if customers can't cover positions. They started limiting the positions that can be taken in some of these names.</p>\n<p>That news came on Jan. 28, which saw GameStop stock price range from over 500 to below 115.</p>\n<p>This is a trade you wanted to watch out for. While some hedge funds were hurt and some retail traders made fortunes — at least on paper — this still may end badly.</p>\n<p>The helium holding these stocks up would not last forever.</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is A Short Squeeze And What Is Going On In GameStop, AMC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is A Short Squeeze And What Is Going On In GameStop, AMC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/how-to-invest/investors-corner/short-squeeze/?src=A00220><strong>investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make truly staggering jumps, doubling in price on consecutive days. There are several factors that are ...</p>\n\n<a href=\"https://www.investors.com/how-to-invest/investors-corner/short-squeeze/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","AMC":"AMC院线"},"source_url":"https://www.investors.com/how-to-invest/investors-corner/short-squeeze/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107758297","content_text":"What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make truly staggering jumps, doubling in price on consecutive days. There are several factors that are contributing to these gargantuan moves, but one is surely the classic short squeeze.\nWhile there are some new factors at play in the markets today, the short squeeze has been around as long as shorting stock.\nWhat Is A Short Squeeze\nHere is how the short squeeze works. If traders think a stock's price is going lower, they canshort the stock. They borrow shares and sell them, with the intent of buying them back at lower prices.\nThis is mostly done by institutional investors, like hedge funds, given the risks and the margin required.\nAnd there are big risks. Stocks can theoretically go up infinitely. So a trader who is short can face theoretically infinite losses.\nSome stocks attract very high short interest, which can be viewed as the amount of shares sold short as a percentage of float, or how much stock has been issued that is available for trading.\nThe problem comes if the stock prices starts to rise quickly. Those that are short the stock will likely receive a margin call. They either have to put more money up to secure their position or close their positions.\nIf they choose to — or are forced to — close their position, they are buying the stock to close out their position. This can push the price higher and force other short sellers to do the same. This creates a reinforcing loop of buying and pushing the price higher. This is the short squeeze, as those short the market get \"squeezed\" out.\nShort Squeeze Stocks: GME\nThis is definitely part of what was happening in GameStop(GME) stock. In August of 2020, GME stock was trading for around 4.\nShares steadily climbed higher to close out 2020 just under 20 on the back of some big name investors taking stakes in the company. This attracted the short sellers, notably some big hedge funds. Then, on Jan. 13, the stock jumped to hit a high of almost 40 on huge volume.\nThat was surely the start of the short squeeze. That 40 level held for about a week. On Jan. 22, the stock jumped again, trading above 70 on the biggest volume day up to that point.\nThe next day the stock hit a high of almost 160 with similar action the next day. Then on Jan. 27 the stock doubled again, trading up to 380. The Jan. 28 high was 483.\nWhile short squeezes are nothing new, this action is unprecedented. The action is certainly partly stock buying by the Reddit group wallstreetbets.\nAnd while many are cheering that the little retail traders are beating up the big institutional shorts, it is pretty clear that other institutions are also in on this buying. Stories have popped up about Michael Burry's gains on GME stock and Elon Musk was tweeting about it.\nHedge Fund Losses\nThere are some big losses in this squeeze.\nTwo funds in particular have been hard hit. Citron Research and Melvin Capital have reportedly suffered huge losses.\nMelvin is down 30% in 2021 on the back of a GME stock short position. It turned to Steven Cohen of Point72 Capital and Chicago-based Citadel to bail it out.\nThe short squeeze is usually something inflicted by one hedge fund on another.\nThis is really the first time we have seen such trading instigated by a band of retail traders.\nOptions Trading Is Also A Big Factor\nAnother piece of this story's plot is the fact that much of the trading in GME and other names like AMC Entertainment(AMC) and BlackBerry(BB) is actually taking place in the options market.\nBullish call buying instead of buying the stock is attractive here because of the leverage it provides and the fact that the positions are limited risk.\nCalls are contracts that give the right to buy the underlying stock for a given price (strike price) until the expiration date.\nThe most that can be lost is the premium paid for the calls.\nBuying calls requires much less capital, so bigger positions can be taken by small traders.\nThis actually adds to the short squeeze effect.\nWhen retail traders buy calls, it is market makers that sell them.\nThe market makers don't want the risk of being short calls, so they do something called delta hedging.\nWhat Is Delta Hedging, And Why It Matters In A Short Squeeze\nDelta hedging calls requires the market makers to buy stock. And because of the nature of calls, when the price of the underlying stock goes up, the market makers have to buy more stock to stay hedged.\nWe might call this the call option squeeze.\nThe problem is that these moves are not based on any fundamental changes in the stocks.\nNot much has changed for GME stock since it was a $4 stock, and certainly not since it was a $16 stock.\nBrokerage firms are very concerned about the volatility of these moves, as they know they may face losses if customers can't cover positions. They started limiting the positions that can be taken in some of these names.\nThat news came on Jan. 28, which saw GameStop stock price range from over 500 to below 115.\nThis is a trade you wanted to watch out for. While some hedge funds were hurt and some retail traders made fortunes — at least on paper — this still may end badly.\nThe helium holding these stocks up would not last forever.","news_type":1,"symbols_score_info":{"AMC":0.9,"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":562,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822924059,"gmtCreate":1634086595328,"gmtModify":1634086595450,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822924059","repostId":"1116686750","repostType":4,"repost":{"id":"1116686750","kind":"news","pubTimestamp":1634080775,"share":"https://ttm.financial/m/news/1116686750?lang=&edition=full","pubTime":"2021-10-13 07:19","market":"hk","language":"en","title":"Hong Kong stock exchange delays morning trading session due to typhoon","url":"https://stock-news.laohu8.com/highlight/detail?id=1116686750","media":"forexlive","summary":"HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delay","content":"<p>HKEX says that with storm signal in effect the session is delayed.</p>\n<p>Securities, derivates trade delayed opening.</p>","source":"lsy1623168602413","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong stock exchange delays morning trading session due to typhoon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong stock exchange delays morning trading session due to typhoon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 07:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012><strong>forexlive</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delayed opening.</p>\n\n<a href=\"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSCCI":"红筹指数","HSTECH":"恒生科技指数","HSCEI":"国企指数","HSI":"恒生指数"},"source_url":"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116686750","content_text":"HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delayed opening.","news_type":1,"symbols_score_info":{"HSCCI":0.9,"HSCEI":0.9,"HSI":0.9,"HSTECH":0.9}},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829746958,"gmtCreate":1633561981456,"gmtModify":1633561981591,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Wow 1 bill","listText":"Wow 1 bill","text":"Wow 1 bill","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829746958","repostId":"2173494802","repostType":4,"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829748320,"gmtCreate":1633561954911,"gmtModify":1633561955107,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829748320","repostId":"2173948202","repostType":4,"repost":{"id":"2173948202","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1633560167,"share":"https://ttm.financial/m/news/2173948202?lang=&edition=full","pubTime":"2021-10-07 06:42","market":"us","language":"en","title":"Wall Street ends higher on optimism about U.S. debt-ceiling deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2173948202","media":"Reuters","summary":"ADP shows U.S. private jobs pick up in September\nAmerican Airlines, Nucor fall on GS downgrades\n\n\nAf","content":"<ul>\n <li>ADP shows U.S. private jobs pick up in September</li>\n <li>American Airlines, Nucor fall on GS downgrades</li>\n</ul>\n<ul>\n <li>Affirm shares jumped closed up 20% after online lender partners with Target ahead of holiday shopping season</li>\n</ul>\n<ul>\n <li>Indexes: Dow +0.30%, S&amp;P 500 +0.41%, Nasdaq +0.47%</li>\n</ul>\n<p>Oct 6 (Reuters) - Wall Street ended higher on Wednesday as investors grew more optimistic that congressional Democrats and Republicans could reach a deal to avert a government debt default.</p>\n<p>Top U.S. Senate Republican Mitch McConnell said his party would support an extension of the federal debt ceiling into December. This would head off a historic default that would exact a heavy economic toll.</p>\n<p>\"McConnell made some dovish comments about temporarily extending the debt ceiling,\" said Jay Hatfield, founder and portfolio manager at Infrastructure Capital Advisors. \"That's going to be interpreted in the short-run as positive.\"</p>\n<p>McConnell's offer could provide an off-ramp to a months-long standoff between President Joe Biden's Democrats and McConnell's Republicans, who had been expected on Wednesday to block a third attempt by Senate Democrats to raise the $28.4 trillion debt ceiling.</p>\n<p>Stocks were lower for much of the session after a strong showing of private jobs in September fueled bets the Federal Reserve could start reining in monetary stimulus soon.</p>\n<p>The Dow Jones Industrial Average rose 0.3% to end at 34,416.99 points, while the S&amp;P 500 gained 0.41% to 4,363.55.</p>\n<p>The Nasdaq Composite climbed 0.47% to 14,501.91.</p>\n<p>Mega-cap growth stocks Amazon and Microsoft both rose more than 1% after the benchmark U.S. 10-year Treasury yield retreated from three-month highs by early afternoon.</p>\n<p>The ADP National Employment Report showed private payrolls increased by 568,000 jobs last month. Economists polled by Reuters had forecast a rise of 428,000 jobs.</p>\n<p>\"Positive labor market data comes with the implication that the Fed can tighten policy at a quicker pace. But the fact that hiring is up shouldn't be discounted — it's definitely a good thing in terms of recovery,\" said Mike Loewengart, managing director, investment strategy at E*TRADE Financial.</p>\n<p>The more comprehensive non-farm payrolls data is due on Friday. It is expected to cement the case for the Fed's slowing of asset purchases.</p>\n<p>Oil prices hit multi-year highs early, but crude prices retreated from those highs while the S&amp;P 500 energy sector index slid over 1%, the weakest performer among 11 sector indexes.</p>\n<p>American Airlines Group fell 4.33% after Goldman Sachs cut its rating on the carrier to \"sell\" from \"neutral\".</p>\n<p>Shares in steelmaker Nucor Corp dropped 2.75% after Goldman Sachs lowered its rating to \"neutral\" from \"buy\".</p>\n<p>Affirm&nbsp;shares jumped closed up 20% on Wednesday after retail chainTargetbegan offering its customers the online lender’s installment loan service for purchases of over $100.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.31-to-1 ratio; on Nasdaq, a 1.58-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 3 new 52-week highs and 9 new lows; the Nasdaq Composite recorded 31 new highs and 241 new lows.</p>\n<p>Volume on U.S. exchanges was 10.6 billion shares, compared with the 11.0 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends higher on optimism about U.S. debt-ceiling deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends higher on optimism about U.S. debt-ceiling deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-07 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>ADP shows U.S. private jobs pick up in September</li>\n <li>American Airlines, Nucor fall on GS downgrades</li>\n</ul>\n<ul>\n <li>Affirm shares jumped closed up 20% after online lender partners with Target ahead of holiday shopping season</li>\n</ul>\n<ul>\n <li>Indexes: Dow +0.30%, S&amp;P 500 +0.41%, Nasdaq +0.47%</li>\n</ul>\n<p>Oct 6 (Reuters) - Wall Street ended higher on Wednesday as investors grew more optimistic that congressional Democrats and Republicans could reach a deal to avert a government debt default.</p>\n<p>Top U.S. Senate Republican Mitch McConnell said his party would support an extension of the federal debt ceiling into December. This would head off a historic default that would exact a heavy economic toll.</p>\n<p>\"McConnell made some dovish comments about temporarily extending the debt ceiling,\" said Jay Hatfield, founder and portfolio manager at Infrastructure Capital Advisors. \"That's going to be interpreted in the short-run as positive.\"</p>\n<p>McConnell's offer could provide an off-ramp to a months-long standoff between President Joe Biden's Democrats and McConnell's Republicans, who had been expected on Wednesday to block a third attempt by Senate Democrats to raise the $28.4 trillion debt ceiling.</p>\n<p>Stocks were lower for much of the session after a strong showing of private jobs in September fueled bets the Federal Reserve could start reining in monetary stimulus soon.</p>\n<p>The Dow Jones Industrial Average rose 0.3% to end at 34,416.99 points, while the S&amp;P 500 gained 0.41% to 4,363.55.</p>\n<p>The Nasdaq Composite climbed 0.47% to 14,501.91.</p>\n<p>Mega-cap growth stocks Amazon and Microsoft both rose more than 1% after the benchmark U.S. 10-year Treasury yield retreated from three-month highs by early afternoon.</p>\n<p>The ADP National Employment Report showed private payrolls increased by 568,000 jobs last month. Economists polled by Reuters had forecast a rise of 428,000 jobs.</p>\n<p>\"Positive labor market data comes with the implication that the Fed can tighten policy at a quicker pace. But the fact that hiring is up shouldn't be discounted — it's definitely a good thing in terms of recovery,\" said Mike Loewengart, managing director, investment strategy at E*TRADE Financial.</p>\n<p>The more comprehensive non-farm payrolls data is due on Friday. It is expected to cement the case for the Fed's slowing of asset purchases.</p>\n<p>Oil prices hit multi-year highs early, but crude prices retreated from those highs while the S&amp;P 500 energy sector index slid over 1%, the weakest performer among 11 sector indexes.</p>\n<p>American Airlines Group fell 4.33% after Goldman Sachs cut its rating on the carrier to \"sell\" from \"neutral\".</p>\n<p>Shares in steelmaker Nucor Corp dropped 2.75% after Goldman Sachs lowered its rating to \"neutral\" from \"buy\".</p>\n<p>Affirm&nbsp;shares jumped closed up 20% on Wednesday after retail chainTargetbegan offering its customers the online lender’s installment loan service for purchases of over $100.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.31-to-1 ratio; on Nasdaq, a 1.58-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 3 new 52-week highs and 9 new lows; the Nasdaq Composite recorded 31 new highs and 241 new lows.</p>\n<p>Volume on U.S. exchanges was 10.6 billion shares, compared with the 11.0 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF","SDS":"两倍做空标普500ETF","OEX":"标普100","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","SSO":"两倍做多标普500ETF","MSFT":"微软",".DJI":"道琼斯","AFRM":"Affirm Holdings, Inc.","AAL":"美国航空",".IXIC":"NASDAQ Composite","AMZN":"亚马逊",".SPX":"S&P 500 Index","NUE":"纽柯钢铁","IVV":"标普500指数ETF","COMP":"Compass, Inc.","SPXU":"三倍做空标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2173948202","content_text":"ADP shows U.S. private jobs pick up in September\nAmerican Airlines, Nucor fall on GS downgrades\n\n\nAffirm shares jumped closed up 20% after online lender partners with Target ahead of holiday shopping season\n\n\nIndexes: Dow +0.30%, S&P 500 +0.41%, Nasdaq +0.47%\n\nOct 6 (Reuters) - Wall Street ended higher on Wednesday as investors grew more optimistic that congressional Democrats and Republicans could reach a deal to avert a government debt default.\nTop U.S. Senate Republican Mitch McConnell said his party would support an extension of the federal debt ceiling into December. This would head off a historic default that would exact a heavy economic toll.\n\"McConnell made some dovish comments about temporarily extending the debt ceiling,\" said Jay Hatfield, founder and portfolio manager at Infrastructure Capital Advisors. \"That's going to be interpreted in the short-run as positive.\"\nMcConnell's offer could provide an off-ramp to a months-long standoff between President Joe Biden's Democrats and McConnell's Republicans, who had been expected on Wednesday to block a third attempt by Senate Democrats to raise the $28.4 trillion debt ceiling.\nStocks were lower for much of the session after a strong showing of private jobs in September fueled bets the Federal Reserve could start reining in monetary stimulus soon.\nThe Dow Jones Industrial Average rose 0.3% to end at 34,416.99 points, while the S&P 500 gained 0.41% to 4,363.55.\nThe Nasdaq Composite climbed 0.47% to 14,501.91.\nMega-cap growth stocks Amazon and Microsoft both rose more than 1% after the benchmark U.S. 10-year Treasury yield retreated from three-month highs by early afternoon.\nThe ADP National Employment Report showed private payrolls increased by 568,000 jobs last month. Economists polled by Reuters had forecast a rise of 428,000 jobs.\n\"Positive labor market data comes with the implication that the Fed can tighten policy at a quicker pace. But the fact that hiring is up shouldn't be discounted — it's definitely a good thing in terms of recovery,\" said Mike Loewengart, managing director, investment strategy at E*TRADE Financial.\nThe more comprehensive non-farm payrolls data is due on Friday. It is expected to cement the case for the Fed's slowing of asset purchases.\nOil prices hit multi-year highs early, but crude prices retreated from those highs while the S&P 500 energy sector index slid over 1%, the weakest performer among 11 sector indexes.\nAmerican Airlines Group fell 4.33% after Goldman Sachs cut its rating on the carrier to \"sell\" from \"neutral\".\nShares in steelmaker Nucor Corp dropped 2.75% after Goldman Sachs lowered its rating to \"neutral\" from \"buy\".\nAffirm shares jumped closed up 20% on Wednesday after retail chainTargetbegan offering its customers the online lender’s installment loan service for purchases of over $100.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.31-to-1 ratio; on Nasdaq, a 1.58-to-1 ratio favored decliners.\nThe S&P 500 posted 3 new 52-week highs and 9 new lows; the Nasdaq Composite recorded 31 new highs and 241 new lows.\nVolume on U.S. exchanges was 10.6 billion shares, compared with the 11.0 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".DJI":0.9,".IXIC":0.9,".SPX":0.9,"AAL":0.9,"AFRM":0.9,"AMZN":0.9,"COMP":0.9,"ESmain":0.9,"IVV":0.9,"MSFT":0.9,"NUE":0.9,"OEF":0.9,"OEX":0.9,"SDS":0.9,"SH":0.9,"SPXU":0.9,"SSO":0.9,"UPRO":0.9}},"isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862621009,"gmtCreate":1632876658893,"gmtModify":1632880628446,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Hahah another fud by motley fool&nbsp;","listText":"Hahah another fud by motley fool&nbsp;","text":"Hahah another fud by motley fool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862621009","repostId":"1156652008","repostType":4,"repost":{"id":"1156652008","kind":"news","pubTimestamp":1632875254,"share":"https://ttm.financial/m/news/1156652008?lang=&edition=full","pubTime":"2021-09-29 08:27","market":"us","language":"en","title":"Why AMC Stock Dropped Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1156652008","media":"Motley Fool","summary":"The move occurred as the broader market was declining, but the movie theater operator also got some ","content":"<blockquote>\n <b>The move occurred as the broader market was declining, but the movie theater operator also got some potentially bad news recently.</b>\n</blockquote>\n<p><b>What happened</b></p>\n<p>Sharp moves in<b>AMC Entertainment</b>'s(NYSE:AMC)share price are nothing new this year. The meme stock has endured big jumps and steeps drops with seemingly no reason beyond the flow of chatter on social media's investing forums. On Tuesday, the U.S. stock market was trending downward, and shares of the theater operator were too. But there has also been some worrisome news recently about a situation that could impact AMC's future. As of 12:10 p.m. EDT, AMC shares were down about 4.3%.</p>\n<p><b>So what</b></p>\n<p>Over the last week, AMC shares are down by almost 6.5%. That drop may have been related to something<b>Walt Disney</b>CEO Bob Chapek said while speaking at the<b>Goldman Sachs</b>Communacopia Conference last Tuesday.</p>\n<p>Even on the heels of the successful theater-only release of Disney's latest Marvel blockbuster,<i>Shang-Chi and the Legend of the Ten Rings</i>, Chapek wouldn't commit to continuing that business model past this year. In fact, he stated that Disney would be flexible with film releases, and implied there will be a mix of debuting movies on its Disney+ streaming service along with various windows fortheater showings.</p>\n<p><b>Now what</b></p>\n<p>Thatis not something AMC shareholders wantto hear. AMC has seen its market cap lifted to $20 billion on the backs of retail traders hoping to profit by punishing short-sellers. But for the company to begin to justify that valuation, the business itself will have to turn around. Moreover, the company needs to pay down the massive debt it took on so it could stay afloat until customers come back to theaters -- assuming they do return in something like their former numbers.</p>\n<p>With Disney failing to commit to releasing movies exclusively in theaters beyond this year, the future of AMC's business remains uncertain. For investors who are paying attention to the outlook for the business, that's another incentive to take profits and move on.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMC Stock Dropped Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMC Stock Dropped Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 08:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/why-amc-stock-dropped-tuesday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The move occurred as the broader market was declining, but the movie theater operator also got some potentially bad news recently.\n\nWhat happened\nSharp moves inAMC Entertainment's(NYSE:AMC)share price...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/why-amc-stock-dropped-tuesday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/why-amc-stock-dropped-tuesday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156652008","content_text":"The move occurred as the broader market was declining, but the movie theater operator also got some potentially bad news recently.\n\nWhat happened\nSharp moves inAMC Entertainment's(NYSE:AMC)share price are nothing new this year. The meme stock has endured big jumps and steeps drops with seemingly no reason beyond the flow of chatter on social media's investing forums. On Tuesday, the U.S. stock market was trending downward, and shares of the theater operator were too. But there has also been some worrisome news recently about a situation that could impact AMC's future. As of 12:10 p.m. EDT, AMC shares were down about 4.3%.\nSo what\nOver the last week, AMC shares are down by almost 6.5%. That drop may have been related to somethingWalt DisneyCEO Bob Chapek said while speaking at theGoldman SachsCommunacopia Conference last Tuesday.\nEven on the heels of the successful theater-only release of Disney's latest Marvel blockbuster,Shang-Chi and the Legend of the Ten Rings, Chapek wouldn't commit to continuing that business model past this year. In fact, he stated that Disney would be flexible with film releases, and implied there will be a mix of debuting movies on its Disney+ streaming service along with various windows fortheater showings.\nNow what\nThatis not something AMC shareholders wantto hear. AMC has seen its market cap lifted to $20 billion on the backs of retail traders hoping to profit by punishing short-sellers. But for the company to begin to justify that valuation, the business itself will have to turn around. Moreover, the company needs to pay down the massive debt it took on so it could stay afloat until customers come back to theaters -- assuming they do return in something like their former numbers.\nWith Disney failing to commit to releasing movies exclusively in theaters beyond this year, the future of AMC's business remains uncertain. For investors who are paying attention to the outlook for the business, that's another incentive to take profits and move on.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":844617599,"gmtCreate":1636422002353,"gmtModify":1636422009758,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh yeah AMD!","listText":"Oh yeah AMD!","text":"Oh yeah AMD!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/844617599","repostId":"2182113779","repostType":4,"isVote":1,"tweetType":1,"viewCount":1501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":809174997,"gmtCreate":1627355274919,"gmtModify":1631891968235,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Nice leh","listText":"Nice leh","text":"Nice leh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/809174997","repostId":"2154966721","repostType":4,"repost":{"id":"2154966721","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627355035,"share":"https://ttm.financial/m/news/2154966721?lang=&edition=full","pubTime":"2021-07-27 11:03","market":"us","language":"en","title":"Why These 3 Microsoft Analysts Are Bullish Ahead Of Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2154966721","media":"Benzinga","summary":"Microsoft Corp. (NASDAQ: MSFT) is set to report fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc and Wedbush Securities have provided insight into the company’s market positioning.","content":"<p><b>Microsoft Corp. </b>(NASDAQ:MSFT) is set to report&nbsp;fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc&nbsp;and Wedbush Securities have provided insight into the company’s market positioning.</p>\n<p>The consensus estimates project fourth-quarter EPS of&nbsp;$1.90 and revenue of&nbsp;$44.1&nbsp;billion.</p>\n<h3>Citi's Take On Microsoft</h3>\n<p>“Recovering IT budgets, an uptick in expected reseller growth, signs of reacceleration in consumption models and slightly higher PC numbers vs. 3 months ago” have helped analyst Tyler Radke maintain a positive outlook for Microsoft’s fourth-quarter earnings. The analyst did not provide an exact EPS estimate.</p>\n<p>Longer-term, Microsoft remains Citi’s top large-cap play among North American application software, systems software, and interactive home entertainment stocks, the analyst said in a note.</p>\n<p>The analyst maintained a Buy rating and raised the&nbsp;price target from $310 to $378.</p>\n<h3>KeyBanc's Take On Microsoft</h3>\n<p>Microsoft is becoming increasingly strategically important in the realm of security, cloud migration&nbsp;and digital transformation, said KeyBanc's managing director and senior analyst of enterprise software Michael Turits.</p>\n<p>According to a survey of IT value-added resellers (VAR), security, Office 365&nbsp;and Azure are the top areas of spending as the world ushers in an enterprise shift to greater adoption of digital technologies, said the analyst.</p>\n<p>The VAR survey additionally highlighted that Microsoft’s products rank highly against competitors, from dev-ops solutions such as GitHub to cloud solutions with Azure to security offerings,&nbsp;which surpassed Okta/Auth0, he said.</p>\n<p>The analyst reiterated an Overweight rating and increased the&nbsp;price target from $305 to $330.</p>\n<h3>Wedbush's Take On Microsoft</h3>\n<p>Analyst Daniel Ives is expecting a “beat and raise” from Microsoft on&nbsp;earnings and guidance Tuesday.</p>\n<p>Azure deal sizes are “increasing markedly,” driven by an acceleration in enterprise-wide digital transformations to cloud architecture, said the analyst.</p>\n<p>Azure is in its early stages of the roll-out, penetrating only 35% of Microsoft’s installed base, he said. Microsoft’s Office 365 transition should continue to provide tailwinds in enterprise Azure adoption, said Ives.</p>\n<p>Digital transformation has an estimated $1 trillion total addressable market, and Microsoft is incredibly well-positioned to deploy Azure and Office 365 as the backbone of cloud enterprise solutions, said the Wedbush analyst.</p>\n<p>Looking ahead, Wedbush maintains its Outperform rating on Microsoft with a $325 price target, mainly due to a growing cloud transformation story fueled by a currently large Microsoft software installed base.</p>\n<p><b>MSFT Price Action: </b>Microsoft was trading down 0.43% to $288.43 at last check Monday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why These 3 Microsoft Analysts Are Bullish Ahead Of Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy These 3 Microsoft Analysts Are Bullish Ahead Of Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-27 11:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Microsoft Corp. </b>(NASDAQ:MSFT) is set to report&nbsp;fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc&nbsp;and Wedbush Securities have provided insight into the company’s market positioning.</p>\n<p>The consensus estimates project fourth-quarter EPS of&nbsp;$1.90 and revenue of&nbsp;$44.1&nbsp;billion.</p>\n<h3>Citi's Take On Microsoft</h3>\n<p>“Recovering IT budgets, an uptick in expected reseller growth, signs of reacceleration in consumption models and slightly higher PC numbers vs. 3 months ago” have helped analyst Tyler Radke maintain a positive outlook for Microsoft’s fourth-quarter earnings. The analyst did not provide an exact EPS estimate.</p>\n<p>Longer-term, Microsoft remains Citi’s top large-cap play among North American application software, systems software, and interactive home entertainment stocks, the analyst said in a note.</p>\n<p>The analyst maintained a Buy rating and raised the&nbsp;price target from $310 to $378.</p>\n<h3>KeyBanc's Take On Microsoft</h3>\n<p>Microsoft is becoming increasingly strategically important in the realm of security, cloud migration&nbsp;and digital transformation, said KeyBanc's managing director and senior analyst of enterprise software Michael Turits.</p>\n<p>According to a survey of IT value-added resellers (VAR), security, Office 365&nbsp;and Azure are the top areas of spending as the world ushers in an enterprise shift to greater adoption of digital technologies, said the analyst.</p>\n<p>The VAR survey additionally highlighted that Microsoft’s products rank highly against competitors, from dev-ops solutions such as GitHub to cloud solutions with Azure to security offerings,&nbsp;which surpassed Okta/Auth0, he said.</p>\n<p>The analyst reiterated an Overweight rating and increased the&nbsp;price target from $305 to $330.</p>\n<h3>Wedbush's Take On Microsoft</h3>\n<p>Analyst Daniel Ives is expecting a “beat and raise” from Microsoft on&nbsp;earnings and guidance Tuesday.</p>\n<p>Azure deal sizes are “increasing markedly,” driven by an acceleration in enterprise-wide digital transformations to cloud architecture, said the analyst.</p>\n<p>Azure is in its early stages of the roll-out, penetrating only 35% of Microsoft’s installed base, he said. Microsoft’s Office 365 transition should continue to provide tailwinds in enterprise Azure adoption, said Ives.</p>\n<p>Digital transformation has an estimated $1 trillion total addressable market, and Microsoft is incredibly well-positioned to deploy Azure and Office 365 as the backbone of cloud enterprise solutions, said the Wedbush analyst.</p>\n<p>Looking ahead, Wedbush maintains its Outperform rating on Microsoft with a $325 price target, mainly due to a growing cloud transformation story fueled by a currently large Microsoft software installed base.</p>\n<p><b>MSFT Price Action: </b>Microsoft was trading down 0.43% to $288.43 at last check Monday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","03086":"华夏纳指","09086":"华夏纳指-U"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154966721","content_text":"Microsoft Corp. (NASDAQ:MSFT) is set to report fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc and Wedbush Securities have provided insight into the company’s market positioning.\nThe consensus estimates project fourth-quarter EPS of $1.90 and revenue of $44.1 billion.\nCiti's Take On Microsoft\n“Recovering IT budgets, an uptick in expected reseller growth, signs of reacceleration in consumption models and slightly higher PC numbers vs. 3 months ago” have helped analyst Tyler Radke maintain a positive outlook for Microsoft’s fourth-quarter earnings. The analyst did not provide an exact EPS estimate.\nLonger-term, Microsoft remains Citi’s top large-cap play among North American application software, systems software, and interactive home entertainment stocks, the analyst said in a note.\nThe analyst maintained a Buy rating and raised the price target from $310 to $378.\nKeyBanc's Take On Microsoft\nMicrosoft is becoming increasingly strategically important in the realm of security, cloud migration and digital transformation, said KeyBanc's managing director and senior analyst of enterprise software Michael Turits.\nAccording to a survey of IT value-added resellers (VAR), security, Office 365 and Azure are the top areas of spending as the world ushers in an enterprise shift to greater adoption of digital technologies, said the analyst.\nThe VAR survey additionally highlighted that Microsoft’s products rank highly against competitors, from dev-ops solutions such as GitHub to cloud solutions with Azure to security offerings, which surpassed Okta/Auth0, he said.\nThe analyst reiterated an Overweight rating and increased the price target from $305 to $330.\nWedbush's Take On Microsoft\nAnalyst Daniel Ives is expecting a “beat and raise” from Microsoft on earnings and guidance Tuesday.\nAzure deal sizes are “increasing markedly,” driven by an acceleration in enterprise-wide digital transformations to cloud architecture, said the analyst.\nAzure is in its early stages of the roll-out, penetrating only 35% of Microsoft’s installed base, he said. Microsoft’s Office 365 transition should continue to provide tailwinds in enterprise Azure adoption, said Ives.\nDigital transformation has an estimated $1 trillion total addressable market, and Microsoft is incredibly well-positioned to deploy Azure and Office 365 as the backbone of cloud enterprise solutions, said the Wedbush analyst.\nLooking ahead, Wedbush maintains its Outperform rating on Microsoft with a $325 price target, mainly due to a growing cloud transformation story fueled by a currently large Microsoft software installed base.\nMSFT Price Action: Microsoft was trading down 0.43% to $288.43 at last check Monday.","news_type":1,"symbols_score_info":{"03086":0.9,"09086":0.9,"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":829748320,"gmtCreate":1633561954911,"gmtModify":1633561955107,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829748320","repostId":"2173948202","repostType":4,"repost":{"id":"2173948202","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1633560167,"share":"https://ttm.financial/m/news/2173948202?lang=&edition=full","pubTime":"2021-10-07 06:42","market":"us","language":"en","title":"Wall Street ends higher on optimism about U.S. debt-ceiling deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2173948202","media":"Reuters","summary":"ADP shows U.S. private jobs pick up in September\nAmerican Airlines, Nucor fall on GS downgrades\n\n\nAf","content":"<ul>\n <li>ADP shows U.S. private jobs pick up in September</li>\n <li>American Airlines, Nucor fall on GS downgrades</li>\n</ul>\n<ul>\n <li>Affirm shares jumped closed up 20% after online lender partners with Target ahead of holiday shopping season</li>\n</ul>\n<ul>\n <li>Indexes: Dow +0.30%, S&amp;P 500 +0.41%, Nasdaq +0.47%</li>\n</ul>\n<p>Oct 6 (Reuters) - Wall Street ended higher on Wednesday as investors grew more optimistic that congressional Democrats and Republicans could reach a deal to avert a government debt default.</p>\n<p>Top U.S. Senate Republican Mitch McConnell said his party would support an extension of the federal debt ceiling into December. This would head off a historic default that would exact a heavy economic toll.</p>\n<p>\"McConnell made some dovish comments about temporarily extending the debt ceiling,\" said Jay Hatfield, founder and portfolio manager at Infrastructure Capital Advisors. \"That's going to be interpreted in the short-run as positive.\"</p>\n<p>McConnell's offer could provide an off-ramp to a months-long standoff between President Joe Biden's Democrats and McConnell's Republicans, who had been expected on Wednesday to block a third attempt by Senate Democrats to raise the $28.4 trillion debt ceiling.</p>\n<p>Stocks were lower for much of the session after a strong showing of private jobs in September fueled bets the Federal Reserve could start reining in monetary stimulus soon.</p>\n<p>The Dow Jones Industrial Average rose 0.3% to end at 34,416.99 points, while the S&amp;P 500 gained 0.41% to 4,363.55.</p>\n<p>The Nasdaq Composite climbed 0.47% to 14,501.91.</p>\n<p>Mega-cap growth stocks Amazon and Microsoft both rose more than 1% after the benchmark U.S. 10-year Treasury yield retreated from three-month highs by early afternoon.</p>\n<p>The ADP National Employment Report showed private payrolls increased by 568,000 jobs last month. Economists polled by Reuters had forecast a rise of 428,000 jobs.</p>\n<p>\"Positive labor market data comes with the implication that the Fed can tighten policy at a quicker pace. But the fact that hiring is up shouldn't be discounted — it's definitely a good thing in terms of recovery,\" said Mike Loewengart, managing director, investment strategy at E*TRADE Financial.</p>\n<p>The more comprehensive non-farm payrolls data is due on Friday. It is expected to cement the case for the Fed's slowing of asset purchases.</p>\n<p>Oil prices hit multi-year highs early, but crude prices retreated from those highs while the S&amp;P 500 energy sector index slid over 1%, the weakest performer among 11 sector indexes.</p>\n<p>American Airlines Group fell 4.33% after Goldman Sachs cut its rating on the carrier to \"sell\" from \"neutral\".</p>\n<p>Shares in steelmaker Nucor Corp dropped 2.75% after Goldman Sachs lowered its rating to \"neutral\" from \"buy\".</p>\n<p>Affirm&nbsp;shares jumped closed up 20% on Wednesday after retail chainTargetbegan offering its customers the online lender’s installment loan service for purchases of over $100.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.31-to-1 ratio; on Nasdaq, a 1.58-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 3 new 52-week highs and 9 new lows; the Nasdaq Composite recorded 31 new highs and 241 new lows.</p>\n<p>Volume on U.S. exchanges was 10.6 billion shares, compared with the 11.0 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends higher on optimism about U.S. debt-ceiling deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends higher on optimism about U.S. debt-ceiling deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-07 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>ADP shows U.S. private jobs pick up in September</li>\n <li>American Airlines, Nucor fall on GS downgrades</li>\n</ul>\n<ul>\n <li>Affirm shares jumped closed up 20% after online lender partners with Target ahead of holiday shopping season</li>\n</ul>\n<ul>\n <li>Indexes: Dow +0.30%, S&amp;P 500 +0.41%, Nasdaq +0.47%</li>\n</ul>\n<p>Oct 6 (Reuters) - Wall Street ended higher on Wednesday as investors grew more optimistic that congressional Democrats and Republicans could reach a deal to avert a government debt default.</p>\n<p>Top U.S. Senate Republican Mitch McConnell said his party would support an extension of the federal debt ceiling into December. This would head off a historic default that would exact a heavy economic toll.</p>\n<p>\"McConnell made some dovish comments about temporarily extending the debt ceiling,\" said Jay Hatfield, founder and portfolio manager at Infrastructure Capital Advisors. \"That's going to be interpreted in the short-run as positive.\"</p>\n<p>McConnell's offer could provide an off-ramp to a months-long standoff between President Joe Biden's Democrats and McConnell's Republicans, who had been expected on Wednesday to block a third attempt by Senate Democrats to raise the $28.4 trillion debt ceiling.</p>\n<p>Stocks were lower for much of the session after a strong showing of private jobs in September fueled bets the Federal Reserve could start reining in monetary stimulus soon.</p>\n<p>The Dow Jones Industrial Average rose 0.3% to end at 34,416.99 points, while the S&amp;P 500 gained 0.41% to 4,363.55.</p>\n<p>The Nasdaq Composite climbed 0.47% to 14,501.91.</p>\n<p>Mega-cap growth stocks Amazon and Microsoft both rose more than 1% after the benchmark U.S. 10-year Treasury yield retreated from three-month highs by early afternoon.</p>\n<p>The ADP National Employment Report showed private payrolls increased by 568,000 jobs last month. Economists polled by Reuters had forecast a rise of 428,000 jobs.</p>\n<p>\"Positive labor market data comes with the implication that the Fed can tighten policy at a quicker pace. But the fact that hiring is up shouldn't be discounted — it's definitely a good thing in terms of recovery,\" said Mike Loewengart, managing director, investment strategy at E*TRADE Financial.</p>\n<p>The more comprehensive non-farm payrolls data is due on Friday. It is expected to cement the case for the Fed's slowing of asset purchases.</p>\n<p>Oil prices hit multi-year highs early, but crude prices retreated from those highs while the S&amp;P 500 energy sector index slid over 1%, the weakest performer among 11 sector indexes.</p>\n<p>American Airlines Group fell 4.33% after Goldman Sachs cut its rating on the carrier to \"sell\" from \"neutral\".</p>\n<p>Shares in steelmaker Nucor Corp dropped 2.75% after Goldman Sachs lowered its rating to \"neutral\" from \"buy\".</p>\n<p>Affirm&nbsp;shares jumped closed up 20% on Wednesday after retail chainTargetbegan offering its customers the online lender’s installment loan service for purchases of over $100.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.31-to-1 ratio; on Nasdaq, a 1.58-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 3 new 52-week highs and 9 new lows; the Nasdaq Composite recorded 31 new highs and 241 new lows.</p>\n<p>Volume on U.S. exchanges was 10.6 billion shares, compared with the 11.0 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF","SDS":"两倍做空标普500ETF","OEX":"标普100","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","SSO":"两倍做多标普500ETF","MSFT":"微软",".DJI":"道琼斯","AFRM":"Affirm Holdings, Inc.","AAL":"美国航空",".IXIC":"NASDAQ Composite","AMZN":"亚马逊",".SPX":"S&P 500 Index","NUE":"纽柯钢铁","IVV":"标普500指数ETF","COMP":"Compass, Inc.","SPXU":"三倍做空标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2173948202","content_text":"ADP shows U.S. private jobs pick up in September\nAmerican Airlines, Nucor fall on GS downgrades\n\n\nAffirm shares jumped closed up 20% after online lender partners with Target ahead of holiday shopping season\n\n\nIndexes: Dow +0.30%, S&P 500 +0.41%, Nasdaq +0.47%\n\nOct 6 (Reuters) - Wall Street ended higher on Wednesday as investors grew more optimistic that congressional Democrats and Republicans could reach a deal to avert a government debt default.\nTop U.S. Senate Republican Mitch McConnell said his party would support an extension of the federal debt ceiling into December. This would head off a historic default that would exact a heavy economic toll.\n\"McConnell made some dovish comments about temporarily extending the debt ceiling,\" said Jay Hatfield, founder and portfolio manager at Infrastructure Capital Advisors. \"That's going to be interpreted in the short-run as positive.\"\nMcConnell's offer could provide an off-ramp to a months-long standoff between President Joe Biden's Democrats and McConnell's Republicans, who had been expected on Wednesday to block a third attempt by Senate Democrats to raise the $28.4 trillion debt ceiling.\nStocks were lower for much of the session after a strong showing of private jobs in September fueled bets the Federal Reserve could start reining in monetary stimulus soon.\nThe Dow Jones Industrial Average rose 0.3% to end at 34,416.99 points, while the S&P 500 gained 0.41% to 4,363.55.\nThe Nasdaq Composite climbed 0.47% to 14,501.91.\nMega-cap growth stocks Amazon and Microsoft both rose more than 1% after the benchmark U.S. 10-year Treasury yield retreated from three-month highs by early afternoon.\nThe ADP National Employment Report showed private payrolls increased by 568,000 jobs last month. Economists polled by Reuters had forecast a rise of 428,000 jobs.\n\"Positive labor market data comes with the implication that the Fed can tighten policy at a quicker pace. But the fact that hiring is up shouldn't be discounted — it's definitely a good thing in terms of recovery,\" said Mike Loewengart, managing director, investment strategy at E*TRADE Financial.\nThe more comprehensive non-farm payrolls data is due on Friday. It is expected to cement the case for the Fed's slowing of asset purchases.\nOil prices hit multi-year highs early, but crude prices retreated from those highs while the S&P 500 energy sector index slid over 1%, the weakest performer among 11 sector indexes.\nAmerican Airlines Group fell 4.33% after Goldman Sachs cut its rating on the carrier to \"sell\" from \"neutral\".\nShares in steelmaker Nucor Corp dropped 2.75% after Goldman Sachs lowered its rating to \"neutral\" from \"buy\".\nAffirm shares jumped closed up 20% on Wednesday after retail chainTargetbegan offering its customers the online lender’s installment loan service for purchases of over $100.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.31-to-1 ratio; on Nasdaq, a 1.58-to-1 ratio favored decliners.\nThe S&P 500 posted 3 new 52-week highs and 9 new lows; the Nasdaq Composite recorded 31 new highs and 241 new lows.\nVolume on U.S. exchanges was 10.6 billion shares, compared with the 11.0 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".DJI":0.9,".IXIC":0.9,".SPX":0.9,"AAL":0.9,"AFRM":0.9,"AMZN":0.9,"COMP":0.9,"ESmain":0.9,"IVV":0.9,"MSFT":0.9,"NUE":0.9,"OEF":0.9,"OEX":0.9,"SDS":0.9,"SH":0.9,"SPXU":0.9,"SSO":0.9,"UPRO":0.9}},"isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":802373672,"gmtCreate":1627725469496,"gmtModify":1631889015157,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Like me pls","listText":"Like me pls","text":"Like me pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802373672","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879786919,"gmtCreate":1636773124448,"gmtModify":1636773124448,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Vaccine","listText":"Vaccine","text":"Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879786919","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://ttm.financial/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":802503651,"gmtCreate":1627785572073,"gmtModify":1631889015157,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"I like Tsla. Like my comment pls","listText":"I like Tsla. Like my comment pls","text":"I like Tsla. Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802503651","repostId":"1169518272","repostType":4,"repost":{"id":"1169518272","kind":"news","pubTimestamp":1627784595,"share":"https://ttm.financial/m/news/1169518272?lang=&edition=full","pubTime":"2021-08-01 10:23","market":"us","language":"en","title":"Telsa Short Squeeze? Why It’s Not Going to Happen","url":"https://stock-news.laohu8.com/highlight/detail?id=1169518272","media":"InvestorPlace\t","summary":"TSLA stock has a large short interest, but don’t expect a short squeeze.Short squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t expect a short squeeze fromTesla. GameStop andAMC Entertainment are just two examples of stocks that skyrocketed this year thanks to short squeezes. Short sellers have always liked TSLA stock. But it takes more than just a large amount of short interest to trigger a short squeeze.The most important factor","content":"<blockquote>\n <b>TSLA stock has a large short interest, but don’t expect a short squeeze.</b>\n</blockquote>\n<p>Short squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t expect a short squeeze from<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>)</p>\n<p><b>GameStop</b>(NYSE:<b><u>GME</u></b>) and<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>) are just two examples of stocks that skyrocketed this year thanks to short squeezes. Short sellers have always liked TSLA stock. But it takes more than just a large amount of short interest to trigger a short squeeze.</p>\n<p>The most important factor when it comes to a short squeeze isn’t total short interest.</p>\n<p><b>Anatomy of a Short Squeeze</b></p>\n<p>It’s short percent of float. A company’s total number of existing shares are its shares outstanding. However, a significant portion of those shares outstanding are typically held by large institutional investors and company insiders. On a standard day in the market, big institutions and company executives aren’t trading millions of dollars of stock.</p>\n<p>Everyone familiar with the basics of a free market knows that price is typically determined by market supply and demand. In the stock market, the number of shares of stock is the supply side of the equation. If company insiders and institutions aren’t selling, their shares aren’t available to contribute to the available market supply.</p>\n<p>A company’s “float” represents the total shares not held by company insiders or institutions. In a practical sense, it represents the effective supply of shares available to trade freely on the market.</p>\n<p>A short squeeze is triggered in part when there is not enough supply of shares to meet demand. That dynamic sends a stock’s share price soaring. And that soaring share price triggers short sellers to cover their positions by buying stock. The more short sellers cover, the bigger the losses remaining short sellers endure.</p>\n<p>At some point, the positive feedback loop hits the point of no return and the stock takes off to the moon.</p>\n<p>Short percent of float is calculated by taking the total short interest and dividing by the total float. It’s a crude estimate of just how explosive a short squeeze could be if all the short sellers are forced to cover all at once.</p>\n<p><b>TSLA Stock vs. GameStop</b></p>\n<p>According toOrtex Analytics, TSLA stock recently had a total short interest of about 32.36 million shares. At a share price of about $645, short sellers were betting $20.87 billion against TSLA stock.</p>\n<p>GameStop recently had about 8 million shares held short, according to Ortex. At a share price of $169, that means GameStop’s total short interest was about $1.35 billion.</p>\n<p>So how is it that GME stock experienced the mother of all short squeezes back in January? Meanwhile, TSLA stock is down 4.7% year-to-date.</p>\n<p>GameStop’s short percent of float recently was about 13.3%. Any number over 10% is relatively high, but it’s nothing crazy for a company like GameStop that is struggling so badly. Tesla’s short percent of float is currently just 4.1%, which is certainly nothing extraordinary.</p>\n<p>Back on Jan. 15, GameStop’s short percent of float was an eye-popping 107.7%. That extremely high short interest coupled with the flood of Reddit traders buying the stock is the reason GME stock skyrocketed from under $20 to as high as $483 in just a couple of weeks. It was a classic short squeeze.</p>\n<p>Since that time, GameStop’s short interest and short percent of float plummeted. It’s no coincidence the stock has dropped back below $165 as well.</p>\n<p><b>What Does This Mean for Tesla?</b></p>\n<p>Yes, short sellers are betting $20.87 billion against Tesla, which is a massive amount of money. But Tesla is a $620 billion company with a huge float. It’s highly unlikely there will ever be the type of supply shortage in TSLA stock that triggered the AMC and GameStop short squeezes earlier this year.</p>\n<p>TSLA stock is not a great short squeeze candidate. Tesla is a story stock. It trades higher or lower based on the story that CEO Elon Musk and other Tesla enthusiasts spread about the company’s potential to completely take over the global auto, energy, technology and transportation industries in the long-term.</p>\n<p>When chapters get added to the story, the stock goes higher. Musk is an excellent storyteller, and he has legions of followers willing to listen to anything he says.</p>\n<p>Byalmost everyobjective fundamental valuation metric, TSLA stock is extremely overvalued. But I have always said story stocks are too dangerous to go long or short. I continue to recommend investors simply stay away from TSLA stock all together.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telsa Short Squeeze? Why It’s Not Going to Happen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelsa Short Squeeze? Why It’s Not Going to Happen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-01 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/tsla-stock-tesla-short-squeeze-why-its-not-going-to-happen/><strong>InvestorPlace\t</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TSLA stock has a large short interest, but don’t expect a short squeeze.\n\nShort squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t ...</p>\n\n<a href=\"https://investorplace.com/2021/07/tsla-stock-tesla-short-squeeze-why-its-not-going-to-happen/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://investorplace.com/2021/07/tsla-stock-tesla-short-squeeze-why-its-not-going-to-happen/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169518272","content_text":"TSLA stock has a large short interest, but don’t expect a short squeeze.\n\nShort squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t expect a short squeeze fromTesla(NASDAQ:TSLA)\nGameStop(NYSE:GME) andAMC Entertainment(NYSE:AMC) are just two examples of stocks that skyrocketed this year thanks to short squeezes. Short sellers have always liked TSLA stock. But it takes more than just a large amount of short interest to trigger a short squeeze.\nThe most important factor when it comes to a short squeeze isn’t total short interest.\nAnatomy of a Short Squeeze\nIt’s short percent of float. A company’s total number of existing shares are its shares outstanding. However, a significant portion of those shares outstanding are typically held by large institutional investors and company insiders. On a standard day in the market, big institutions and company executives aren’t trading millions of dollars of stock.\nEveryone familiar with the basics of a free market knows that price is typically determined by market supply and demand. In the stock market, the number of shares of stock is the supply side of the equation. If company insiders and institutions aren’t selling, their shares aren’t available to contribute to the available market supply.\nA company’s “float” represents the total shares not held by company insiders or institutions. In a practical sense, it represents the effective supply of shares available to trade freely on the market.\nA short squeeze is triggered in part when there is not enough supply of shares to meet demand. That dynamic sends a stock’s share price soaring. And that soaring share price triggers short sellers to cover their positions by buying stock. The more short sellers cover, the bigger the losses remaining short sellers endure.\nAt some point, the positive feedback loop hits the point of no return and the stock takes off to the moon.\nShort percent of float is calculated by taking the total short interest and dividing by the total float. It’s a crude estimate of just how explosive a short squeeze could be if all the short sellers are forced to cover all at once.\nTSLA Stock vs. GameStop\nAccording toOrtex Analytics, TSLA stock recently had a total short interest of about 32.36 million shares. At a share price of about $645, short sellers were betting $20.87 billion against TSLA stock.\nGameStop recently had about 8 million shares held short, according to Ortex. At a share price of $169, that means GameStop’s total short interest was about $1.35 billion.\nSo how is it that GME stock experienced the mother of all short squeezes back in January? Meanwhile, TSLA stock is down 4.7% year-to-date.\nGameStop’s short percent of float recently was about 13.3%. Any number over 10% is relatively high, but it’s nothing crazy for a company like GameStop that is struggling so badly. Tesla’s short percent of float is currently just 4.1%, which is certainly nothing extraordinary.\nBack on Jan. 15, GameStop’s short percent of float was an eye-popping 107.7%. That extremely high short interest coupled with the flood of Reddit traders buying the stock is the reason GME stock skyrocketed from under $20 to as high as $483 in just a couple of weeks. It was a classic short squeeze.\nSince that time, GameStop’s short interest and short percent of float plummeted. It’s no coincidence the stock has dropped back below $165 as well.\nWhat Does This Mean for Tesla?\nYes, short sellers are betting $20.87 billion against Tesla, which is a massive amount of money. But Tesla is a $620 billion company with a huge float. It’s highly unlikely there will ever be the type of supply shortage in TSLA stock that triggered the AMC and GameStop short squeezes earlier this year.\nTSLA stock is not a great short squeeze candidate. Tesla is a story stock. It trades higher or lower based on the story that CEO Elon Musk and other Tesla enthusiasts spread about the company’s potential to completely take over the global auto, energy, technology and transportation industries in the long-term.\nWhen chapters get added to the story, the stock goes higher. Musk is an excellent storyteller, and he has legions of followers willing to listen to anything he says.\nByalmost everyobjective fundamental valuation metric, TSLA stock is extremely overvalued. But I have always said story stocks are too dangerous to go long or short. I continue to recommend investors simply stay away from TSLA stock all together.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":877689986,"gmtCreate":1637924331182,"gmtModify":1637924331182,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Hooray","listText":"Hooray","text":"Hooray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877689986","repostId":"1190474385","repostType":4,"isVote":1,"tweetType":1,"viewCount":1959,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":837933922,"gmtCreate":1629851686666,"gmtModify":1631889015126,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/837933922","repostId":"2162087564","repostType":4,"repost":{"id":"2162087564","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629836173,"share":"https://ttm.financial/m/news/2162087564?lang=&edition=full","pubTime":"2021-08-25 04:16","market":"us","language":"en","title":"Wall St extends rally, pushing S&P 500 to 50th all-time high close this year","url":"https://stock-news.laohu8.com/highlight/detail?id=2162087564","media":"Reuters","summary":"NEW YORK, Aug 24 (Reuters) - Wall Street ended higher in a late-summer, light volume rally on Tuesda","content":"<p>NEW YORK, Aug 24 (Reuters) - Wall Street ended higher in a late-summer, light volume rally on Tuesday as the FDA's full approval of a COVID-19 vaccine on Monday and the absence of negative catalysts kept risk appetite alive ahead of the much-anticipated Jackson Hole Symposium.</p>\n<p>All three major U.S. stock indexes advanced higher, with the S&amp;P 500 and the Nasdaq closing at all-time closing highs.</p>\n<p>The session marked the S&amp;P 500's 50th record high close so far this year.</p>\n<p>Tech and tech-adjacent megacaps were once again doing the heavy lifting, but economically sensitive cyclicals and smallcaps&nbsp;outperformed the broader market.</p>\n<p>\"Investors are looking at the horizon at the big Jackson Hole meeting on the horizon,\" Ryan Detrick, senior market strategist at LPL Financial in Charlotte, North Carolina, referring to the Federal Reserve’s annual economic symposium on Friday. \"But for now the feel-good from yesterday’s vaccine news is still in the air.\"</p>\n<p>The Food and Drug Administration's full approval of the Pfizer-BioNTech COVID-19 vaccine on Monday fueled optimism over economic recovery which spilled into Tuesday's session.</p>\n<p>Travel and leisure sectors, associated with economic re-engagement, outperformed the broader market. The S&amp;P 1500 Airline and Hotel/Restaurant/Leisure indexes gained up 3.7% and 1.6%, respectively.</p>\n<p>\"We have energy, retail, travel, leisure, financials, and small caps all doing well today,\" Detrick said. \"And that’s a sign that the reopening is alive and well.\"</p>\n<p>Recent economic indicators suggest the recovery from the most abrupt recession in U.S. history is headed in the right direction, but not to the extent that is likely to prompt the Fed to tighten its dovish monetary policy.</p>\n<p>Fed Chair Jerome Powell is due to meet with other world bank leaders when the Jackson Hole Symposium convenes later this week, and his remarks will be closely parsed for any clues regarding the Fed's tapering of asset purchases and hiking key interest rates.</p>\n<p>The event will take place virtually and not in person due to the spread of COVID-19 in the county, which has reduced expectations that any major announcement will be made at the event.</p>\n<p>\"The fact that the Fed is having a virtual (Jackson Hole) meeting tells you that they might be thinking maybe they need to keep supporting the economy,\" said Detrick.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 30.55 points, or 0.09%, to 35,366.26, the S&amp;P 500&nbsp;gained 6.7 points, or 0.15%, to 4,486.23 and the Nasdaq Composite&nbsp;added 77.15 points, or 0.52%, to 15,019.80.</p>\n<p>Energy&nbsp;was the top gainer among the 11 major sectors in the S&amp;P 500, boosted by the continued rally in crude prices.</p>\n<p>Best Buy Co Inc&nbsp;jumped 8.3% after the electronics retailer beat analyst earnings expectations and raised its full year sales forecast.</p>\n<p>U.S.-listed shares of China-based e-commerce platform Pinduoduo Inc&nbsp;surged 22.2% after reporting its first ever quarterly profit.</p>\n<p>JD.com&nbsp;gained 14.4% in the wake of the Chinese online retailer's remarks on Monday that it does not expect any business impact from a wave of regulations hitting the industry at home.</p>\n<p>Other shares of Chinese companies listed on U.S. exchanges were bouncing back as well, with the Invesco Golden Dragon ETF&nbsp;jumping 8.0%.</p>\n<p>Cybersecurity firm <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> Inc&nbsp;advanced18.6% as brokerages raised their price targets following its full-year forecast beat.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.17-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 28 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 96 new highs and 37 new lows.</p>\n<p>Volume on U.S. exchanges was 8.97 billion shares, compared with the 9.08 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St extends rally, pushing S&P 500 to 50th all-time high close this year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St extends rally, pushing S&P 500 to 50th all-time high close this year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-25 04:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Aug 24 (Reuters) - Wall Street ended higher in a late-summer, light volume rally on Tuesday as the FDA's full approval of a COVID-19 vaccine on Monday and the absence of negative catalysts kept risk appetite alive ahead of the much-anticipated Jackson Hole Symposium.</p>\n<p>All three major U.S. stock indexes advanced higher, with the S&amp;P 500 and the Nasdaq closing at all-time closing highs.</p>\n<p>The session marked the S&amp;P 500's 50th record high close so far this year.</p>\n<p>Tech and tech-adjacent megacaps were once again doing the heavy lifting, but economically sensitive cyclicals and smallcaps&nbsp;outperformed the broader market.</p>\n<p>\"Investors are looking at the horizon at the big Jackson Hole meeting on the horizon,\" Ryan Detrick, senior market strategist at LPL Financial in Charlotte, North Carolina, referring to the Federal Reserve’s annual economic symposium on Friday. \"But for now the feel-good from yesterday’s vaccine news is still in the air.\"</p>\n<p>The Food and Drug Administration's full approval of the Pfizer-BioNTech COVID-19 vaccine on Monday fueled optimism over economic recovery which spilled into Tuesday's session.</p>\n<p>Travel and leisure sectors, associated with economic re-engagement, outperformed the broader market. The S&amp;P 1500 Airline and Hotel/Restaurant/Leisure indexes gained up 3.7% and 1.6%, respectively.</p>\n<p>\"We have energy, retail, travel, leisure, financials, and small caps all doing well today,\" Detrick said. \"And that’s a sign that the reopening is alive and well.\"</p>\n<p>Recent economic indicators suggest the recovery from the most abrupt recession in U.S. history is headed in the right direction, but not to the extent that is likely to prompt the Fed to tighten its dovish monetary policy.</p>\n<p>Fed Chair Jerome Powell is due to meet with other world bank leaders when the Jackson Hole Symposium convenes later this week, and his remarks will be closely parsed for any clues regarding the Fed's tapering of asset purchases and hiking key interest rates.</p>\n<p>The event will take place virtually and not in person due to the spread of COVID-19 in the county, which has reduced expectations that any major announcement will be made at the event.</p>\n<p>\"The fact that the Fed is having a virtual (Jackson Hole) meeting tells you that they might be thinking maybe they need to keep supporting the economy,\" said Detrick.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 30.55 points, or 0.09%, to 35,366.26, the S&amp;P 500&nbsp;gained 6.7 points, or 0.15%, to 4,486.23 and the Nasdaq Composite&nbsp;added 77.15 points, or 0.52%, to 15,019.80.</p>\n<p>Energy&nbsp;was the top gainer among the 11 major sectors in the S&amp;P 500, boosted by the continued rally in crude prices.</p>\n<p>Best Buy Co Inc&nbsp;jumped 8.3% after the electronics retailer beat analyst earnings expectations and raised its full year sales forecast.</p>\n<p>U.S.-listed shares of China-based e-commerce platform Pinduoduo Inc&nbsp;surged 22.2% after reporting its first ever quarterly profit.</p>\n<p>JD.com&nbsp;gained 14.4% in the wake of the Chinese online retailer's remarks on Monday that it does not expect any business impact from a wave of regulations hitting the industry at home.</p>\n<p>Other shares of Chinese companies listed on U.S. exchanges were bouncing back as well, with the Invesco Golden Dragon ETF&nbsp;jumping 8.0%.</p>\n<p>Cybersecurity firm <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> Inc&nbsp;advanced18.6% as brokerages raised their price targets following its full-year forecast beat.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.17-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 28 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 96 new highs and 37 new lows.</p>\n<p>Volume on U.S. exchanges was 8.97 billion shares, compared with the 9.08 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".IXIC":"NASDAQ Composite","SPXU":"三倍做空标普500ETF",".SPX":"S&P 500 Index","OEX":"标普100","SPY":"标普500ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","SSO":"两倍做多标普500ETF",".DJI":"道琼斯","SH":"标普500反向ETF","IVV":"标普500指数ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162087564","content_text":"NEW YORK, Aug 24 (Reuters) - Wall Street ended higher in a late-summer, light volume rally on Tuesday as the FDA's full approval of a COVID-19 vaccine on Monday and the absence of negative catalysts kept risk appetite alive ahead of the much-anticipated Jackson Hole Symposium.\nAll three major U.S. stock indexes advanced higher, with the S&P 500 and the Nasdaq closing at all-time closing highs.\nThe session marked the S&P 500's 50th record high close so far this year.\nTech and tech-adjacent megacaps were once again doing the heavy lifting, but economically sensitive cyclicals and smallcaps outperformed the broader market.\n\"Investors are looking at the horizon at the big Jackson Hole meeting on the horizon,\" Ryan Detrick, senior market strategist at LPL Financial in Charlotte, North Carolina, referring to the Federal Reserve’s annual economic symposium on Friday. \"But for now the feel-good from yesterday’s vaccine news is still in the air.\"\nThe Food and Drug Administration's full approval of the Pfizer-BioNTech COVID-19 vaccine on Monday fueled optimism over economic recovery which spilled into Tuesday's session.\nTravel and leisure sectors, associated with economic re-engagement, outperformed the broader market. The S&P 1500 Airline and Hotel/Restaurant/Leisure indexes gained up 3.7% and 1.6%, respectively.\n\"We have energy, retail, travel, leisure, financials, and small caps all doing well today,\" Detrick said. \"And that’s a sign that the reopening is alive and well.\"\nRecent economic indicators suggest the recovery from the most abrupt recession in U.S. history is headed in the right direction, but not to the extent that is likely to prompt the Fed to tighten its dovish monetary policy.\nFed Chair Jerome Powell is due to meet with other world bank leaders when the Jackson Hole Symposium convenes later this week, and his remarks will be closely parsed for any clues regarding the Fed's tapering of asset purchases and hiking key interest rates.\nThe event will take place virtually and not in person due to the spread of COVID-19 in the county, which has reduced expectations that any major announcement will be made at the event.\n\"The fact that the Fed is having a virtual (Jackson Hole) meeting tells you that they might be thinking maybe they need to keep supporting the economy,\" said Detrick.\nThe Dow Jones Industrial Average rose 30.55 points, or 0.09%, to 35,366.26, the S&P 500 gained 6.7 points, or 0.15%, to 4,486.23 and the Nasdaq Composite added 77.15 points, or 0.52%, to 15,019.80.\nEnergy was the top gainer among the 11 major sectors in the S&P 500, boosted by the continued rally in crude prices.\nBest Buy Co Inc jumped 8.3% after the electronics retailer beat analyst earnings expectations and raised its full year sales forecast.\nU.S.-listed shares of China-based e-commerce platform Pinduoduo Inc surged 22.2% after reporting its first ever quarterly profit.\nJD.com gained 14.4% in the wake of the Chinese online retailer's remarks on Monday that it does not expect any business impact from a wave of regulations hitting the industry at home.\nOther shares of Chinese companies listed on U.S. exchanges were bouncing back as well, with the Invesco Golden Dragon ETF jumping 8.0%.\nCybersecurity firm Palo Alto Networks Inc advanced18.6% as brokerages raised their price targets following its full-year forecast beat.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.17-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored advancers.\nThe S&P 500 posted 28 new 52-week highs and one new low; the Nasdaq Composite recorded 96 new highs and 37 new lows.\nVolume on U.S. exchanges was 8.97 billion shares, compared with the 9.08 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".DJI":0.9,".IXIC":0.9,".SPX":0.9,"ESmain":0.9,"IVV":0.9,"OEF":0.9,"OEX":0.9,"SDS":0.9,"SH":0.9,"SPXU":0.9,"SPY":0.9,"SSO":0.9,"UPRO":0.9}},"isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":845842779,"gmtCreate":1636331128796,"gmtModify":1636331128935,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845842779","repostId":"1125924899","repostType":4,"repost":{"id":"1125924899","kind":"news","pubTimestamp":1636330179,"share":"https://ttm.financial/m/news/1125924899?lang=&edition=full","pubTime":"2021-11-08 08:09","market":"hk","language":"en","title":"Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record","url":"https://stock-news.laohu8.com/highlight/detail?id=1125924899","media":"Reuters","summary":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply","content":"<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.</p>\n<p>Operating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.</p>\n<p>Net income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).</p>\n<p>Berkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.</p>\n<p>The buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.</p>\n<p>\"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"</p>\n<p>Berkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.</p>\n<p>\"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones &amp; Co analyst who rates Berkshire a \"buy.\"</p>\n<p>DISRUPTIONS</p>\n<p>Third-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.</p>\n<p>Analysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.</p>\n<p>Net income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.</p>\n<p>Berkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.</p>\n<p>It said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.</p>\n<p>In part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.</p>\n<p>\"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo &amp; Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.</p>\n<p>CATASTROPHE LOSSES</p>\n<p>Results reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.</p>\n<p>Geico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.</p>\n<p>In contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.</p>\n<p>Buffett's failure to buy more stocks and companies has disappointed some investors and analysts.</p>\n<p>It stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.</p>\n<p>\"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.</p>\n<p>CFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.</p>\n<p>\"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, <a href=\"https://laohu8.com/S/AONE.U\">one</a> can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 08:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused ...</p>\n\n<a href=\"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125924899","content_text":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.\nOperating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.\nNet income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).\nBerkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.\nThe buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.\n\"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"\nBerkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.\n\"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones & Co analyst who rates Berkshire a \"buy.\"\nDISRUPTIONS\nThird-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.\nAnalysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.\nNet income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.\nBerkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.\nIt said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.\nIn part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.\n\"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo & Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.\nCATASTROPHE LOSSES\nResults reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.\nGeico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.\nIn contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.\nBuffett's failure to buy more stocks and companies has disappointed some investors and analysts.\nIt stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.\n\"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.\nCFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.\n\"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, one can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.","news_type":1,"symbols_score_info":{"BRK.A":0.9,"BRK.B":0.9}},"isVote":1,"tweetType":1,"viewCount":1716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854245705,"gmtCreate":1635465395781,"gmtModify":1635465395921,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854245705","repostId":"1147570640","repostType":4,"repost":{"id":"1147570640","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635463369,"share":"https://ttm.financial/m/news/1147570640?lang=&edition=full","pubTime":"2021-10-29 07:22","market":"us","language":"en","title":"Gilead trims 2021 sales forecast for non-COVID products","url":"https://stock-news.laohu8.com/highlight/detail?id=1147570640","media":"Reuters","summary":"Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earning","content":"<p>Oct 28 (Reuters) - Gilead Sciences Inc&nbsp;on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.</p>\n<p>Without Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.</p>\n<p>Gilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.</p>\n<p>The biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.</p>\n<p>\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.</p>\n<p>The company's shares, which closed at $67.34, were down 2% at $66 in extended trading.</p>\n<p><img src=\"https://static.tigerbbs.com/bb57f1c1d44cce1af6c37e25db1f4a49\" tg-width=\"847\" tg-height=\"621\" width=\"100%\" height=\"auto\"></p>\n<p>Gilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.</p>\n<p>Revenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.</p>\n<p>But the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.</p>\n<p>Gilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.</p>\n<p>Use of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.</p>\n<p>Third-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.</p>\n<p>Sales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.</p>\n<p>Gilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.</p>\n<p>Including Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead trims 2021 sales forecast for non-COVID products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead trims 2021 sales forecast for non-COVID products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-29 07:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Oct 28 (Reuters) - Gilead Sciences Inc&nbsp;on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.</p>\n<p>Without Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.</p>\n<p>Gilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.</p>\n<p>The biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.</p>\n<p>\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.</p>\n<p>The company's shares, which closed at $67.34, were down 2% at $66 in extended trading.</p>\n<p><img src=\"https://static.tigerbbs.com/bb57f1c1d44cce1af6c37e25db1f4a49\" tg-width=\"847\" tg-height=\"621\" width=\"100%\" height=\"auto\"></p>\n<p>Gilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.</p>\n<p>Revenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.</p>\n<p>But the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.</p>\n<p>Gilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.</p>\n<p>Use of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.</p>\n<p>Third-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.</p>\n<p>Sales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.</p>\n<p>Gilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.</p>\n<p>Including Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147570640","content_text":"Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.\nWithout Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.\nGilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.\nThe biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.\n\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.\nThe company's shares, which closed at $67.34, were down 2% at $66 in extended trading.\n\nGilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.\nRevenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.\nBut the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.\nGilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.\nUse of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.\nThird-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.\nSales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.\nGilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.\nIncluding Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822924059,"gmtCreate":1634086595328,"gmtModify":1634086595450,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822924059","repostId":"1116686750","repostType":4,"repost":{"id":"1116686750","kind":"news","pubTimestamp":1634080775,"share":"https://ttm.financial/m/news/1116686750?lang=&edition=full","pubTime":"2021-10-13 07:19","market":"hk","language":"en","title":"Hong Kong stock exchange delays morning trading session due to typhoon","url":"https://stock-news.laohu8.com/highlight/detail?id=1116686750","media":"forexlive","summary":"HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delay","content":"<p>HKEX says that with storm signal in effect the session is delayed.</p>\n<p>Securities, derivates trade delayed opening.</p>","source":"lsy1623168602413","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong stock exchange delays morning trading session due to typhoon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong stock exchange delays morning trading session due to typhoon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 07:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012><strong>forexlive</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delayed opening.</p>\n\n<a href=\"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSCCI":"红筹指数","HSTECH":"恒生科技指数","HSCEI":"国企指数","HSI":"恒生指数"},"source_url":"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116686750","content_text":"HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delayed opening.","news_type":1,"symbols_score_info":{"HSCCI":0.9,"HSCEI":0.9,"HSI":0.9,"HSTECH":0.9}},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":815449529,"gmtCreate":1630715866161,"gmtModify":1631889015116,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Tooooo","listText":"Tooooo","text":"Tooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815449529","repostId":"2164803577","repostType":4,"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808073842,"gmtCreate":1627547417086,"gmtModify":1631891968221,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Why","listText":"Why","text":"Why","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808073842","repostId":"1107279498","repostType":4,"isVote":1,"tweetType":1,"viewCount":311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800830974,"gmtCreate":1627289614698,"gmtModify":1631891968246,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Discounts hooray","listText":"Discounts hooray","text":"Discounts hooray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/800830974","repostId":"1189912829","repostType":4,"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":871399532,"gmtCreate":1637023887635,"gmtModify":1637023887694,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Ywah","listText":"Ywah","text":"Ywah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871399532","repostId":"1140879609","repostType":4,"isVote":1,"tweetType":1,"viewCount":2739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852945165,"gmtCreate":1635237168906,"gmtModify":1635237630982,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Congrats Tiger","listText":"Congrats Tiger","text":"Congrats Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/852945165","repostId":"1134836974","repostType":4,"repost":{"id":"1134836974","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635235567,"share":"https://ttm.financial/m/news/1134836974?lang=&edition=full","pubTime":"2021-10-26 16:06","market":"us","language":"en","title":"UP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=1134836974","media":"Tiger Newspress","summary":"BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” o","content":"<p>BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.</p>\n<p>The Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.</p>\n<p>About UP Fintech Holding Limited</p>\n<p>UP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.</p>\n<p>For more information on the Company, please visit：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-26 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.</p>\n<p>The Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.</p>\n<p>About UP Fintech Holding Limited</p>\n<p>UP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.</p>\n<p>For more information on the Company, please visit：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TIGR":"老虎证券"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134836974","content_text":"BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.\nThe Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.\nAbout UP Fintech Holding Limited\nUP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.\nFor more information on the Company, please visit：https://ir.itiger.com","news_type":1,"symbols_score_info":{"TIGR":0.9}},"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":891530007,"gmtCreate":1628397494309,"gmtModify":1631889015133,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Like liker likest","listText":"Like liker likest","text":"Like liker likest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/891530007","repostId":"2157492883","repostType":4,"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":842838016,"gmtCreate":1636160870694,"gmtModify":1636160948481,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Cheers","listText":"Cheers","text":"Cheers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842838016","repostId":"1173813098","repostType":4,"repost":{"id":"1173813098","kind":"news","pubTimestamp":1636156499,"share":"https://ttm.financial/m/news/1173813098?lang=&edition=full","pubTime":"2021-11-06 07:54","market":"us","language":"en","title":"Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=1173813098","media":"Reuters","summary":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains ","content":"<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.</p>\n<p>The S&amp;P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.</p>\n<p>The Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.</p>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.</p>\n<p>The news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.</p>\n<p>\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.</p>\n<p>The Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&amp;P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.</p>\n<p>For the week, the S&amp;P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.</p>\n<p>Travel stocks rose following Pfizer's announcement, with the S&amp;P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.</p>\n<p>\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.</p>\n<p>Among S&amp;P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.</p>\n<p>Healthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.</p>\n<p>Shares of so-called \"stay-at-home\" names fell, with <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications down 6.2% and Netflix Inc off 3.4%.</p>\n<p>Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.</p>\n<p>Pinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.</p>\n<p>Peloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.</p>\n<p>About 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 07:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19167545><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19167545\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","PFE":"辉瑞",".SPX":"S&P 500 Index"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19167545","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173813098","content_text":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.\nThe S&P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.\nThe Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.\nA trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.\nThe news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.\n\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.\nThe Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.\nFor the week, the S&P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.\nTravel stocks rose following Pfizer's announcement, with the S&P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.\n\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.\nAmong S&P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.\nHealthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.\nShares of so-called \"stay-at-home\" names fell, with Zoom Video Communications down 6.2% and Netflix Inc off 3.4%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.\nPinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.\nPeloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.\nThe S&P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.\nAbout 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857460294,"gmtCreate":1635555751407,"gmtModify":1635555751407,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857460294","repostId":"2179240376","repostType":4,"repost":{"id":"2179240376","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635543522,"share":"https://ttm.financial/m/news/2179240376?lang=&edition=full","pubTime":"2021-10-30 05:38","market":"us","language":"en","title":"U.S. Supreme Court rejects religious challenge to Maine vaccine mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2179240376","media":"Reuters","summary":"WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeki","content":"<p>WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeking a religious exemption to Maine's COVID-19 vaccine mandate in the latest battle over vaccination to reach the justices.</p>\n<p>The court rejected a request made by nine unnamed plaintiffs who identified themselves as healthcare workers who object to receiving the shots on religious grounds. The court previously rejected challenges to vaccine mandates in New York and Indiana, though those cases did not involve religious objections.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Supreme Court rejects religious challenge to Maine vaccine mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Supreme Court rejects religious challenge to Maine vaccine mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-30 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeking a religious exemption to Maine's COVID-19 vaccine mandate in the latest battle over vaccination to reach the justices.</p>\n<p>The court rejected a request made by nine unnamed plaintiffs who identified themselves as healthcare workers who object to receiving the shots on religious grounds. The court previously rejected challenges to vaccine mandates in New York and Indiana, though those cases did not involve religious objections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179240376","content_text":"WASHINGTON, Oct 29 (Reuters) - The U.S. Supreme Court on Friday turned away healthcare workers seeking a religious exemption to Maine's COVID-19 vaccine mandate in the latest battle over vaccination to reach the justices.\nThe court rejected a request made by nine unnamed plaintiffs who identified themselves as healthcare workers who object to receiving the shots on religious grounds. The court previously rejected challenges to vaccine mandates in New York and Indiana, though those cases did not involve religious objections.","news_type":1,"symbols_score_info":{"STS":0.9}},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852945931,"gmtCreate":1635237133809,"gmtModify":1635237630604,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh wow nice","listText":"Oh wow nice","text":"Oh wow nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/852945931","repostId":"1111450640","repostType":4,"isVote":1,"tweetType":1,"viewCount":417,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}